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ABSTRACT

CHARACTERIZATION OF A NOVEL NUCLEAR VARIANT OF BMP2

Jaime L. Mayo
Department of Microbiology and Molecular Biology
Doctor of Philosophy

Bone morphogenetic protein 2 (Bmp2) is a signaling protein that was first
detected by its ability to induce cartilage and bone formation. It has since been implicated
in broad variety of developmental, patterning, and disease processes. To date, Bmp2 has
only been known to function as an extracellular signaling molecule. However, we have
obtained clear evidence for a nuclear form of Bmp2. This nuclear variant, nBmp2,
contains a bipartite NLS that overlaps the site of proteolytic cleavage. The NLS remains
intact and functional when translation of Bmp2 initiates from a downstream alternative
start codon. The resulting protein lacks the signal peptide and is therefore translated in
the cytoplasm rather than the endoplasmic reticulum, thus avoiding proteolytic
processing and secretion. Instead, the uncleaved protein containing the intact NLS is
translocated to the nucleus. Preliminary functional analyses in zebrafish indicate that
nBmp2 is critical for proper heart development. To determine if this function is
conserved in mammals, we have also generated mice harboring a null allele for nBmp2.

ABSTRACT

COORDINATE REGULATION OF COL11A2 AND COL27A1 BY THE
TRANSCRIPTION FACTOR LC-MAF

Jaime L. Mayo
Department of Microbiology and Molecular Biology
Doctor of Philosophy

During skeletal development, long bones of the body develop from a cartilage
template that is progressively replaced by bone. This process of endochondral ossification
requires precisely coordinated expression of extracellular matrix proteins such as the
cartilage-specific collagens. In this study, enhancer/reporter assays demonstrated that the
transcription factor Lc-Maf inhibits the transcriptional activity of a cartilage-specific
Col11a2 enhancer element while a cartilage-specific COL27A1 enhancer element was
strongly activated by Lc-Maf. Site-directed mutagenesis identified the binding region
within the COL27A1 enhancer, and it was found to be unlike any known consensus Maf
family binding site. The in vivo significance of these results was examined using
immunohistochemistry and in situ hybridization in mouse limbs undergoing
endochondral ossification. Taken together, these results suggest that Lc-Maf participates
in the developmental transition from proliferating to hypertrophic chondrocytes during
endochondral ossification by coordinately downregulating Col11a2 and upregulating
Col27a1 collagen gene expression.
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BOOK I

CHARACTERIZATION OF A NOVEL NUCLEAR
VARIANT OF BMP2

xiv

INTRODUCTION
Bmp2
Bone morphogenetic protein 2 (Bmp2) is a member of the transforming growth
factor beta (TGFβ) superfamily of secreted signaling molecules. With over 20 members,
the BMP subfamily constitutes the largest subfamily in the TGFβ superfamily (Mishina,
2003). BMPs were first detected in the 1960s for their ability to induce ectopic cartilage
and bone formation when implanted into rodents (Urist, 1965). Since that time, Bmp2 has
been implicated in broad variety of highly conserved cellular and developmental
processes. In Drosophilia, the Bmp2 homologue Decapentaplegic (Dpp) participates in
wing imaginal disc development and axis formation (Raftery and Sutherland, 1999).
Similarly, in vertebrates Bmp2 has been shown to play important roles in limb
development and specification of left identity during left-right axis formation (Hogan,
1996; Schlange et al., 2002). In addition to these roles, Bmp2 also plays a role in
proliferation of spermatogonia (Puglisi et al., 2004). Blockage of Bmp2 signaling in the
cranial neural crest prevents cell migration, and mice homozygous for a null Bmp2 allele
have lethal defects in the amnion/chorion and heart (Kanzler et al., 2000; Zhang and
Bradley, 1996). Bmp2 is known to be expressed in the developing forebrain, gut,
pituitary, limb bud, tooth buds, kidney, notochord, axial skeleton, skull sutures,
interdigital mesenchyme, and in hair follicles (Drossopoulou et al., 2000; Dudley and
Robertson, 1997; Furuta et al., 1997; Kim et al., 1992; Kim et al., 1998; Lyons et al.,
1995; Lyons et al., 1990; St-Jacques et al., 1998; Wozney, 1992).
Not surprisingly given its multifunctionality, Bmp2 has also been shown to play a
complex role in a variety of cancers. It was shown to stimulate angiogenesis in
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developing tumors in mice and to be overexpresssed in a majority of lung carcinomas
(Langenfeld et al., 2005; Langenfeld et al., 2003; Langenfeld and Langenfeld, 2004;
Raida et al., 2005; Usami et al., 2005). In contrast to these findings, Bmp2 induces
apoptosis in human myeloma cells and has also been shown to decrease the proliferation
of human prostate cancer cells, gastric cancer cells, and breast cancer cells (Arnold et al.,
1999; Kawamura et al., 2000; Tomari et al., 2005; Wen et al., 2004). Also, its loss is
associated with increased progression of prostate cancer to a more aggressive phenotype
(Horvath et al., 2004).
It was determined in the 1960s that extracts from demineralized bone could
induce new bone formation when implanted into ectopic sites in rodents. The proteins
responsible for this bone-inducting effect remained unknown until the purification and
sequencing of bovine bmp3 (osteogenin) and cloning of human BMP2, 3, and 4 in the
late 1980s (Luyten et al., 1989; Wozney et al., 1988). Since that time, much has been
revealed about the structure and function of Bmp2. The gene encoding murine Bmp2
spans approximately 11 kb and contains three exons including the noncoding exon 1 and
coding exons 2 and 3. Like other TGFβ superfamily ligands, Bmp2 is synthesized as a
large preproprotein precursor that consists of a signal peptide that directs translation to
the rough endoplasmic reticulum (rER) and consequently the secretory pathway, a
propeptide, and a C-terminal mature peptide (Wang et al., 1990). In the trans-Golgi
apparatus, Bmp2 is cleaved after the proprotein convertase recognition sequence R-E-KR-↓ which is a consensus sequence for a number of proprotein convertases located within
secretory pathway compartments (Constam and Robertson, 1999). This cleavage releases
the C-terminal mature peptide from the propeptide. The C-terminal peptide then

2

homodimerizes through disulfide bonds to form the mature secreted growth factor before
being secreted from the cell (Chen et al., 2004; Wozney, 1989).
At least two distinct pathways mediate Bmp signaling: the canonical Smad
pathway and a mitogen-activated protein kinase (MAPK) pathway. Bmp2, like other
members of the TGFβ family, binds to and induces apposition of type I and type II
serine/threonine kinase receptors. This causes the type II receptor to phosphorylate
serine/threonine residues in the type I receptors. Activated type I receptors phosphorylate,
and thereby activate, Smad proteins 1, 5, and 8. These Smads subsequently recruit and
bind Smad4 to form heteromeric complexes, which are then translocated to the nucleus
and bind DNA directly or interact with DNA binding proteins to regulate the
transcription of target genes (Chen et al., 2004; Moustakas and Heldin, 2002). Bmp2 has
also been shown to signal through non-Smad pathways involving the activation of JNK
and p38 MAPK (Gallea et al., 2001; Guicheux et al., 2003; Lemonnier et al., 2004).
Nuclear proteins
Bmp2 has previously been recognized only as a secreted growth factor. However,
we have identified a variant form of Bmp2 that is translated from a downstream
alternative start codon and subsequently localized to the nucleus. Although Bmp2 has not
previously been found in the nucleus, nuclear forms of several other signaling molecules
have been identified. For example, parathyroid hormone-related peptide (PTHrP) is a
secreted protein which has an alternate nuclear form. Much like Bmp2, the nuclear form
of PTHrP is translated from a downstream alternative start site, enabling it to bypass
translation in the ER and eventual secretion (Nguyen et al., 2001). Basic fibroblast
growth factor (bFGF) and fibroblast growth factor 3 (FGF3) also have both secreted and
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nuclear forms (Amalric et al., 1991; Antoine et al., 1997; Bugler et al., 1991; Kiefer et al.,
1994). The nuclear forms of bFGF and FGF3 result when translation occurs upstream of
the conventional start codons, resulting in the inclusion of amino acid sequences that
direct the finished peptides to the nucleus.
Most nuclear proteins contain nuclear-localizing amino acid sequences called
nuclear localization sequences (NLSs) that target the protein to the nucleus. The first of
such signal sequences identified was in the simian virus 40 (SV40) large-T antigen
(Kalderon et al., 1984a; Kalderon et al., 1984b). That sequence, PKKKRK, and the
sequence found in nucleoplasmin, KRPAATKKAGQAKKKKLD (with basic amino
acids key to nuclear localization underlined and in bold), are the prototypes for the
monopartite and bipartite nuclear localization signals (NLSs). It is now known that these
signals function by binding to a large variety of soluble transport factors called
karyopherins that are able to shuttle NLS-containing proteins into the nucleus (Corbett
and Silver, 1997).
The machinery responsible for active transport of proteins into the nucleus of cells
consists of the nuclear pore complex (NPC) and a subgroup of karyopherins called
importins that not only interact with the various NLSs of nuclear proteins but also with
the proteins of the NPC (Fried and Kutay, 2003; Macara, 2001; Pemberton and Paschal,
2005). The most common transport system is the importin α/importin β-dependent
pathway for nuclear import (Fried and Kutay, 2003; Macara, 2001; Pemberton and
Paschal, 2005). In this system, importin α serves as an adapter between the nuclear
protein and importin β: it binds directly to the NLS and then to importin β through a
characteristic importin β-binding- (IBB-) domain. This complex of nuclear
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protein/importin α/importin β translocates through the NPC and then dissociates in the
nucleus. While this is the most commonly used and best characterized transport system, a
number of other mechanisms exist. For example, transportin is a transport receptor that
does not require an adapter molecule to bind to the nuclear proteins. Interestingly,
another transport receptor that can function independently of an adapter molecule is
importin β itself. It has been shown to be responsible for the importin α-independent
nuclear import of proteins such as PTHrP (Lam et al., 2002), cyclin B1 (Moore et al.,
1999), the transcription factors c-Jun, c-Fos and CREB (Forwood et al., 2001), and the
zinc finger transcription factor Snail (Yamasaki et al., 2005). The HIV-1 Rev protein can
be localized to the nucleus by multiple importins: importin β (independently of importin
α), transportin, importin 5, and importin 7 (Arnold et al., 2006).
Herein we report the existence of a previously unidentified variant of Bmp2,
nuclear Bmp2 (nBmp2). We have demonstrated that nBmp2 is directed to the nucleus
through a bipartite NLS that spans the site of proteolytic cleavage. This bipartite NLS is
able to localize Bmp2 to the nucleus when translation initiates from an alternative,
downstream start codon. The resulting protein lacks the signal peptide and is therefore
translated in the cytoplasm rather than the rER, thus avoiding proteolytic processing and
secretion and gaining access to the karyopherins responsible for nuclear import. In order
to determine the function of nBmp2 in an animal model, a targeting vector was created to
inhibit nuclear localization but allow for normal secretion and function of Bmp2.
Chimeric mice carrying this defective allele have been generated, and the processes of
breeding to homozygosity is underway. Preliminary results in zebrafish strongly suggest
a critical role for nBmp2 in heart development.
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METHODS
GFP fusion constructs
When we first became interested in a putative nuclear form of Bmp2, we analyzed
its amino acid sequence using the PSORT II prediction program (Prediction of Protein
Sorting Signals and Localization Sites in Amino Acid Sequences) to search for possible
NLSs. Three were identified: NLSa, NLSb, and NLSc. To determine the functionality of
each of the putative NLSs identified by PSORT II, each was fused to the C-terminal end
of GFP to determine whether they were capable of directing GFP to the nucleus. The
pCMV/GFP-NLSa, pCMV/GFP-NLSb, and pCMV/GFP-NLSc constructs were
generated by annealing complementary oligonucleotides encoding NLSa (PELGRKK),
NLSb (PLHKREK), and NLSc (PLHKREKRQAKHKQRKRLKS) with additional
nucleotides to create NotI or PstI ends, allowing ligation into an appropriate site in the
pCMV/myc/ER/GFP vector. In addition, pCMV/GFP-NLSa/b was generated by
inserting NLSa N-terminal of GFP and NLSb C-terminal of GFP in order to mimic the
way NLSa and NLSb bracket the free propeptide that is released upon proteolytic
cleavage of the Bmp2 preproprotein (Fig. 1). pCMV/myc/ER/GFP was used as a control
in transfection experiments, with an inserted stop codon immediately after GFP.
An expression vector for wtBmp2 was generated by synthesizing cDNA from
mRNA extracted from rat chondrosarcoma (RCS) cells using the Qiagen OneStep RTPCR kit (Qiagen,Valencia, CA) according to manufacturer’s instructions. Primers were
used for PCR amplification that included a BamHI site and a XbaI site to allow ligation
into the expression vector pcDNA3.1. This plasmid was used as a template for the
production of the Bmp2/GFP fusion constructs using a GFP Fusion TOPO TA
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Expression Kit (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s
instructions.

Site-directed mutagenesis
The Stratagene QuikChange II Site-Directed Mutagenesis Kit was used to mutate
specific nucleotides in the Bmp2/GFP and Bmp2 expression vectors. The manufacturer’s
protocol was followed with the following specifications: 20 ng of template DNA and 125
ng of each primer were used during the thermal cycling portion. The template DNA was
then fragmented by incubating the reaction mixture with 1 µL DpnI at 37°C for 1 hour.
The mutagenesis primers used to study the bipartite NLS are as follows with the altered
nucleotides bold and underlined:
NtermKm F:GGACATCCACTCCACGCACGAGAAAAGCGTCAAGCC
NtermKm R:GGCTTGACGCTTTTCTCGTGCGTGGAGTGGATGTCC
KRm F:GGACATCCACTCCACGCAGCAGAAAAGCGTCAAGCC
KRm R:GGCTTGACGCTTTTCTGCTGCGTGGAGTGGATGTCC
RKRm1 F:GCCAAACACAAACAGGCGGAGCGTCTTAAGTCCAGCTGCAAAAG
RKRm1 R:CTTTTGCAGCTGGACTTAAGACGCTCCGCCTGTTTGTGTTTGGC
RKRm2 F:GCCAAACACAAACAGGCGGCGGCTCTTAAGTCCAGCTGCAAAAG
RKRm2 R:CTTTTGCAGCTGGACTTAAGAGCCGCCGCCTGTTTGTGTTTGGC
RKR Km F: CACAAACAGGCGGCGGCTCTTGCGTCCAGCTGCAAGAG
RKR Km R: CTCTTGCAGCTGGACGCAAGAGCCGCCGCCTGTTTGTG
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All oligonucleotides were synthesized by Invitrogen Life Technologies. All
constructs were verified by DNA sequencing (DNA Sequencing Center, Brigham Young
University).

Transient transfection, fixing, and analysis
All tissue culture cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with penicillin (50U/ml), streptomycin (50µg/ml), L-glutamine
(2 mM), and 10% fetal bovine serum at 37°C under 5% CO2. The cells were passaged
every 3-4 days. For transient DNA transfections, 5×104 cells were seeded into each well
of a 4-chambered Lab-Tek II Chamber Slide System glass slide (ISC Bioexpress). After
24 hours, the cells were transfected using the TransIT-Jurkat Transfection Reagent
(Mirus, Madison WI) according to manufacturer’s directions, with a total of 500 ng DNA
and 1.5 µL Jurkat reagent for each well. The transfected cells were incubated for
approximately 24 hours at which time the media was replaced. After another 24 hours,
the cells were washed in Phosphate Buffered Saline (PBS) and fixed using 4%
paraformaldehyde in PBS (PFA/PBS) for 30 minutes. After fixing, the slide was washed
three times in PBS and the nuclei were stained with a 1:1000-1:1500 dilution of TOPRO-3 iodide (Invitrogen Corporation, Carlsbad, CA) according to manufacturer’s
protocol. Cells were mounted in Fluoromount-G (Southern Biotech, Birmingham, AL)
and coverslipped (Fisher, Santa Clara, CA).
The cells were analyzed using an Olympus IX81 laser confocal microscope at 60×
magnification, with excitation wavelengths of 488 nm for GFP and 633 nm for TO-PRO3. The percentage of transfected cells exhibiting nuclear localization was determined by
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counting approximately 100 transfected cells per well. Each experiment was repeated at
least three times and the average of the three experiments is reported.

Immunocytochemistry
To visualize the localization of endogenous Bmp2, immunohistochemistry was
performed on the following cultured tissue lines: RCS, BALB/3T3 fibroblasts, 10T1/2
mesenchyme cells, 231 breast cancer cells, 435 breast cancer cells, MCF-7 breast cancer
cells, Hep-G2 liver cancer cells, HT29 colon cancer cells, and a primary culture of mouse
embryonic fibroblasts (MEFs). Either 50,000 or 25,000 cells were seeded into each well
of a 4-chambered Lab-Tek II Chamber Slide System glass slide (ISC Bioexpress) and
grown for 2 days. The media was then removed, and the cells were rinsed twice with 0.4
mL PBS. The cells were fixed with 200 µL of 4% PFA/PBS in each well for 20-30
minutes with gentle agitation. After the incubation, the slides were rinsed three times
with 0.4 mL PBS, twice for 5 minutes and once for 20 minutes. The well dividers were
then removed and the cells were incubated for 40 minutes in 300 µL blocking solution:
1% BSA and 0.3% Triton X-100 in PBS. This solution was removed and 300 µL of the
primary antibody solution was added: 0.1% BSA, 0.3% Triton X-100, and 1:50 dilution
of a goat polyclonal anti-Bmp2 antibody (Santa Cruz Biologicals, Santa Cruz, CA) or a
rabbit polyclonal anti-Bmp2 antibody (AbCam, Cambridge, MA). The slides were
incubated in this solution at room temperature for 2 hours and then placed at 4°C in a
humid chamber overnight. The following day, the slides were rinsed three times for 5
minutes each in PBS and then incubated for 30-45 minutes in the secondary antibody
solution: 0.1% BSA, 0.3% Triton X-100, and 6 µg/mL donkey anti-goat 488-labeled
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secondary antibody or a goat anti-rabbit 488-labeled secondary antibody (Molecular
Probes). After this incubation the slides were again rinsed three times for 5 minutes each
in PBS. The nuclei were stained with TO-PRO-3 iodide, rinsed, coverslipped, and
examined using a laser confocal microscope as detailed above. As a negative control,
cells were incubated as detailed above without primary antibody.

Western blot analysis on nuclear extracts
To determine the size of nBmp2, western blots were performed on nuclear
extracts from either non-transfected cultured cells or cultured cells that were transfected
with an HA-tagged nBmp2 expression vector (HA-ERmBmp2). The TransIT-Jurkat
Transfection Reagent (Mirus, Madison, WI) was used to transfect the cells according to
manufacturer’s directions. Specifically, 1600 µL of Opti-MEM was combined with 50 µL
Jurkat reagent for 10 minutes at room temperature before 16 µg of the HA-ERmBmp2
expression plasmid was added. This mixture was incubated for 15 minutes at room
temperature then added to one 75-cm2 tissue culture flask of cells with fresh complete
media. The cells were allowed to grow for 24 hours with the transfection reagent before
the media was replaced with new complete media and grown for 24 more hours.
Nuclear proteins were isolated using the Cellytic Nuclear Extraction Kit (Sigma,
Saint Louis, MO) according to manufacturer’s instructions. Specifically, the cells were
rinsed twice in cold PBS, collected, and centrifuged in a tabletop centrifuge at 4°C for 5
minutes at 2000 rpm. The cells were lysed in 500 µL hypotonic lysis buffer (provided by
manufacturer) for 15 minutes on ice before centrifuging again in a tabletop centrifuge at
4°C for 5 minutes at 2000 rpm. After decanting and resuspending the cell pellet in 200

10

µL lysis buffer, the cells were disrupted with a 27-gauge needle and syringe. The nuclei
were subsequently collected by centrifuging at 4°C for 20 minutes at 8500 rpm. Nuclear
proteins were extracted by adding 150 µL extraction buffer (supplied by manufacturer)
and incubating at 4°C for 30 minutes in a rotisserie shaker. Supernatants containing the
nuclear proteins were flash-frozen in liquid N2 and stored at -80°C.
Nuclear proteins were fractionated by SDS-PAGE using 10% gels and transferred
to Westran Clear Signal PVDF transfer membranes (Schleicher and Schuell, Keene, NH)
overnight at 30 volts using Tris glycine buffer (25 mM Tris, 192 mM glycine, 20%
methanol, pH 8.3). The membranes were rinsed with TBS-t (0.05 M Tris-HCl, pH 7.5,
0.2 M NaCl, 0.1% Tween-20) and blocked in 2.5% non-fat dry milk (Bio-Rad, Hercules,
CA) in TBS-t for 1 hour with gentle agitation on an orbital shaker. The membrane with
the nuclear proteins from non-transfected cells was then incubated with a 1:250 dilution
of goat anti-Bmp2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) while the
membrane with the nuclear proteins from the HA-ERmBmp2-transfected cells was
incubated with a 1:250 dilution of rabbit anti-HA antibody (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) for 1 hour in 2.5% non-fat dry milk. After a 20-minute wash and
two 5-minute washes with agitation in TBS-t, the membranes were incubated in the
appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) for1 hour in 2.5% non-fat dry milk. The washes were performed again
as described. To visualize the proteins, the Immobilon Western Chemilumiescent HRP
Substrate (Millipore, Billerica, MA) was used according to manufacture’s protocol.
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In vitro transcription translation and in vitro digestion assay
Bmp2 protein was synthesized in vitro with the incorporation of [35S]methionine
employing the TNT Coupled Wheat Germ Extract System (Promega, Madison, WI)
according to manufacturer’s instruction using an expression vector containing the rat
Bmp2 cDNA. Ten units of furin (New England BioLabs, Ipswich, MA) or furin plus 2
µM α1-PDX (Affinity BioReagents, Golden, CO) was preincubated in 100 mM HEPES,
0.5% Triton X-100, 1 mM CaCl2 and 1 mM β-mercaptoethanol for 30 minutes at room
temperature. The synthesized and labeled Bmp2 proprotein was then added, and the
reaction was allowed to proceed for 1 hour or 3 hours at 30°C before products were
separated by SDS-PAGE and visualized by autoradiography.
The TNT Coupled Wheat Germ Extract System (Promega, Madison, WI) was
also used to transcribe and translate the ATG mutant constructs for the alternative start
codon experiments and for the zebrafish bmp4/morpholino translation experiments.

Immunoprecipitation/Western blot of wild-type and RKRm Bmp2
To determine if mutating the RKR portion of the bipartite NLS would affect the
processing and secretion of Bmp2, RCS cells were transfected with either the HA-tagged
wtBmp2 (HA-wtBmp2) or RKRm (HA-RKRmBmp2) expression plasmids and allowed
to grow for two days before the HA-tagged proteins were immunoprecipitated from the
media and subjected to immunoblotting. To do this, two 25-cm2 tissue culture flasks were
seeded with 7.8 ×105 RCS cells. The following day, 5 µg of either the HA-wtBmp2 or
HA-RKRmBmp2 expression plasmids was transfected into the cells using the TransITJurkat Transfection Reagent (Mirus, Madison, WI) according to manufacturer’s protocol.
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Specifically, 625 µL of Opti-MEM was combined with 16.7 µL Jurkat reagent for 10
minutes at room temperature before the plasmid DNA was added. This mixture was
incubated for 15 minutes at room temperature then added to the cells with fresh complete
media. The cells were allowed to grow for 24 hours with the transfection reagent before
the media was replaced with new complete media and grown for 24 more hours.
After the cells had grown for 48 hours from the start of transfection, 1.5 mL of
media was removed from each flask and 2 µL of the protease Leupeptin was added to
each sample. The media was centrifuged for 10 minutes at 10,000 rpm to remove cellular
debris. The HA-tagged proteins were precipitated using EZview Red Anti-HA Affinity
Gel (Sigma, Saint Louis, MO) according to manufacturer’s protocol as follows. For
immunoprecipitation, 40 µL of the affinity gel was added to a clean microcentrifuge tube
on ice and equilibrated by adding 750 µL of PBS, mixing, and centrifuging for 30
seconds at 8,200 × g. The PBS was aspirated and the wash was repeated. The media from
the flasks of transfected cells was then added to the affinity gel and incubated at 4°C for 2
hours with rotation. After the incubation, the affinity gel and bound HA-tagged proteins
were pelleted by centrifuging for 30 seconds at 8,200 × g and the media aspirated. The
gel was washed three times for 5 minutes each with 750 µL PBS. The HA-tagged
proteins were removed from the resin by adding 40 µL Laemmli buffer with 5% βmercaptoethanol and boiling for 5 minutes.
The samples were immediately fractionated by SDS-PAGE using a 10% gel and
transferred to a Westran Clear Signal PVDF transfer membrane (Schleicher and Schuell,
Keene, NH) overnight at 30 volts using Tris glycine buffer as detailed above. The
membranes were rinsed with TBS-t and blocked in 2.5% non-fat dry milk (Bio-Rad,

13

Hercules, CA) in TBS-t for 1 hour with gentle agitation on an orbital shaker. After a 20minute wash and two 5-minute washes with agitation in TBS-t, the membrane was
incubated with 0.7 µg/mL HRP-conjugated anti-HA antibody for 1 hour in 2.5% non-fat
dry milk. The washes were performed again as described. To visualize the HA-tagged
proteins, the ECL Western blotting reagent (Amersham Biosciences, Piscataway, NJ) was
used according to manufacturer’s protocol.

Microarray and Real-Time PCR
A microarray was performed through Assuragen to identify genes that might be
responsive to nBmp2. We used real-time PCR to verify the results. To collect mRNA for
the microarray and for real-time PCR, RCS cells were transfected with an expression
vector for nuclear Bmp2. This construct, ERmutBmp2, lacked the sequence coding for
the signal peptide and would thus be translated in the cytosol and subsequently localized
to the nucleus. As a control, cells were also transfected with the empty pcDNA3.1 vector.
For real-time PCR, another flask of cells was transfected with a nuclear GFP expression
vector to use as a control (NLScGFP). The RNA was extracted from these cells using the
NucleoSpin RNA II Kit (Clontech, Mountain View, CA) according to manufacturer’s
protocol. Specifically, the cells were incubated with trypsin, collected in 15-mL conical
vials, and centrifuged for 9 minutes at 800 RPM. The media was aspirated and the cells
were resuspended in 350 µL of the provided Buffer RA1 and 3.5 µL of βmercaptoethanol. The sample was passed through a syringe fitted with a 20-gauge needle
six times to completely homogenize the cells and shear genomic DNA. To the lysate, 350
µL of 70% ethanol was added and mixed well. The sample was loaded onto a NucleoSpin
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column and centrifuged at 8000 × g for 30 seconds. The flow-through was discarded and
350 µL of the provided Buffer MDB was added before centrifuging at 11000 × g for 1
minute. The flow-through was again discarded and 95 µL of DNase I Reaction Mixture
was added and incubated for 15 minutes at room temperature before adding 200 µL of the
provided Buffer RA2 and centrifuging at 8000 × g for 30 seconds. The flow through was
again discarded and 600 µL of the provided Buffer RA3 was added to the column and
centrifuged again at 8000 × g for 30 seconds. The flow through was discarded and the
column was again washed with Buffer RA3, this time with 250 µL and centrifuging at
11000 × g for 2 minutes. The RNA was eluted in two steps into two 1.5-mL
microcentrifuge tubes, each with 40 µL of nuclease-free water and centrifuging at 11000
× g for 1 minute.
For the microarray analysis, three biological replicates of RNA from
ERmutBmp2-transfected cells and three biological replicates of RNA from the vectortransfected cells were shipped to Assuragen according to their instructions. RNA was
analyzed on Affymetrix Rat Expression Arrays 230 2.0. Differentially expressed genes
were selected using two-tailed student t statistics comparing expression values from the
ERmutBmp2-transfected samples and the replicate data from the vector-transfected
controls. A p-value of <0.05 and a fold-change of >1.5 fold in either direction were
considered significant.
To verify the microarray results, real-time PCR was performed on a number of
genes that were indicated as being differentially expressed and perhaps regulated by
nBmp2. For these assays, RNA from nuclear GFP-transfected cells was included to
control for genes that may be responding to overexpression of any nuclear protein,
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perhaps as a stress response. The extracted RNA was reverse transcribed into cDNA
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to
manufacturer’s protocol. Specifically, the following components were combined in a
PCR tube: 4 µL 5 × iScript Reaction Mix, 1 µL iScript Reverse Transcriptase, 600-900
µg RNA template, and nuclease-free water to a total volume of 20 µL. The reaction
components were mixed, placed in a thermocycler and subjected to the following
program: 5 minutes at 25°C, 30 minutes at 42°C, and 5 minutes at 85°C.
For the real-time PCR reaction, the iTaq SYBR Green Supermix with ROX (BioRad, Hercules, CA) was initially used, but we later switched to the LightCycler 480
SYBR Green I Master (Roche, Indianapolis, IN) not only because it was designed for the
machine we were using but also because it had higher sensitivity. For the Roche kit, each
reaction contained 300 ng of cDNA template, 10 µL of the Master Mix, 0.5 µL of 10 µM
forward and reverse primer, and water up to 20 µL. The reactions were placed into wells
of a 96-well plate, sealed shut using Optically Clear Thermalseal (ISC BioExpress,
Kaysville, UT), and centrifuged.
Raw real-time PCR results were expressed as Cp (“crossing point”) values and
were analyzed using the - ∆∆Cp method as follows: the Cp value for each sample was
normalized by subtracting the corresponding 18S rRNA average Cp value from each
reaction (e.g. the 18S Cp values for the ERmutBmp2 template were averaged and
subtracted from all wells using the ERmutBmp2 cDNA as template). To calculate
differences in gene expression between ERmutBmp2-transfected cells and vectortransfected controls, normalized ERmutBmp2 Cp values were then subtracted from the
control Cp values, resulting in a ∆∆Cp value. Fold difference in Cp values between
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ERmutBmp2-transfected cells and vector-transfected controls was calculated by raising 2
to the –∆∆Cp. To calculate the fold differences in the RNA levels, the fold differences in
the Cp values from 2-4 experiments were averaged, then the average fold difference in
Cp values of the vector-transfected controls was divided by the average fold difference in
Cp values for the ERmutBmp2-transfected cells.

Construction of the nBmp2 knock-out targeting vector
The nuclear Bmp2-knockout targeting vector was constructed using
recombineering (recombination-mediated genetic engineering) (Copeland et al., 2001).
This technique uses a modified E. coli strain containing defective λ prophage
recombination genes (strain SW102). A temperature-sensitive repressor controls the
expression of the λ recombination genes exo, bet, and gam, allowing for induction of
recombination to occur upon heating the cells. exo encodes a 5′-3′ exonuclease that acts
on the 5′ ends of linear double-strand DNA (dsDNA) to produce 3′ single-strand DNA
(ssDNA) overhangs. bet encodes a pairing protein, Beta, that binds to the 3′ end of the
ssDNA overhangs and promotes annealing to its complementary DNA strands on the
target DNA. The Gam protein inhibits the RecBCD exonuclease of the host E. coli
allowing the linear dsDNA to remain stable.
Primers
PCR and sequencing primers used for construction the nuclear Bmp2 knockout
vector are listed below:
5′ Bmp2 Forward, gaatgcggccgcCTGTCTCGAGAATGAGC;
5′ Bmp2 Reverse, gctaaagcttGAAGGCTGAGGCAAGGCTG;
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3′ Bmp2 Forward, gaataagcttCACAGCAGGCCCCATGTGAC;
3′ Bmp2 Reverse, ggtcactagtGCTCAGCATGTCAGCACCCAG;
5′ Neo Forward, gttaggtaccGATCTGATAGAAAACGTCTCGC;
5′ Neo Reverse, gttagtcgacGGGTGCTTTGGAGAATAGAG;
3′ Neo Forward, gaccgaattcCGCAGCAAAATTGAGCATATG;
3′ Neo Reverse, gaacgaattcCATTGGTAAGTCCTTTGGTCCAAC;
3′ Neo sequencing, GACGAGTTCTTCTGAGGGGATC;
PGK-EM7 Forward,
aagacagaataaaacgcacgggtgttgggtcgtttgttcggtcgagctcgcgaaTCTACCGGGTAGGGGAGG;

PGK-EM7 Reverse,
aacctgcgtgcaatccatcttgttcaatggccgatcccatattggctgcacggatGGTTTAGTTCCTCACCTTGTC;

galK Forward,
aaaggacatccgctccacaaacgagaaaagcgtcaagccaaacacaaacagCCTGTTGACAATTAATCATCGGCA;

galK Reverse,
acatcactgaagtccacatacaaagggtgtctcttgcagctggacttgagTCAGCACTGTCCTGCTCCTT;

NLS sequencing, GGTCTTTGCACCAAGATGAAC;
Minitargvec Reverse, TCCAACTGGGGTTTGCTTAG;
Genotyping Forward, GGCCATTTAGAGGAGAACC;
Genotyping Reverse, CATGCCTTAGGGATTTTGGA.
Homology to the sequence being amplified is capitalized while sequence containing
restriction endonuclease recognition site and/or homology arms is lowercase. The
primers to amplify homology arms amplified the following size fragments: 5′ Bmp2
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homology arm: 329 bp; 3′ Bmp2 homology arm: 329 bp; 5′ Neo insertion arm: 327 bp; 3′
Neo insertion arm: 341 bp.
Plasmid Construction
Neo mini-targeting vector
The ACN selection cassette was used in the targeting vector because this cassette
not only contains the necessary neomycin resistance (Neo) gene, but also it contains the
Cre recombinase gene. Cre is the 38-kDa product of the Cre (cyclization recombination)
gene of bacteriophage P1 and is a site-specific DNA recombinase. Cre recognizes a 34-bp
site on the P1 genome called loxP (locus of X-over of P1) and efficiently catalyzes
reciprocal conservative DNA recombination between pairs of loxP sites. The Neo
cassettes used in targeting vectors are generally flanked (“floxed”) by loxP sites and the
generated mice are then bred with a strain of mice that express Cre to remove the
cassette. However, the ACN cassette contains the Cre gene and a testis-specific promoter
(tACE from the gene encoding angiotensin-converting enzyme 27) that drives its
expression in the male germline. Consequently, there is no need for extra breeding steps
when the generated mice contain this cassette.
In order to make the ACN selection cassette functional for selection in bacterial
cells as well as in eukaryotic cells so that it could be used in the recombineering
technique, the eukaryotic Pol II promoter that drove expression of Neo was replaced by
the combined eukaryotic PGK and bacterial EM7 promoters described by Liu et al. (Liu
et al., 2003). PCR amplification (Invitrogen PLATINUM Taq DNA polymerase) of the
PGK-EM7 promoters was performed using reaction mixtures containing 5 µL 10x PCR
buffer minus Mg, 1 µL of 10 mM dNTP mixture, 1.5 µL of 50 mM MgCl2, 1 µL of 10
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µM forward primer, 1 µL of 10 µM reverse primer, 1 µL of 50 ng/µL PL451, 0.3 µL of 5
U/µL PLATINUM Taq DNA Polymerase and 40.2 µL of water. Four reactions were
performed to acquire adequate amounts of the desired product. The PCR products were
purified via a 1% agarose gel followed by extraction from the gel using the Qiagen Qiaex
II kit (Qiagen, Qiagen,Valencia, CA) according to manufacturer’s instructions. The
samples were pooled and ethanol precipitated using 0.2 M NaCl and 10 mM MgCl2.
SW102 cells already containing pACN were induced for recombination at 42°C for 15
minutes in a water bath to induce the λ recombination proteins and electroporated with
100 ng of the purified PGK-EM7 promoters.
Insertion of the promoters introduced an additional SpeI recognition site into
pACN, so correctly recombined plasmids were identified via digestion with SpeI. Since
one successful homologous recombination event could render the cell kanamycin
resistant and pACN is a multi-copy plasmid, it was not surprising that all plasmid
extractions consisted of mixed populations of recombined and non-recombined plasmids.
To remedy this, SW102 cells were transformed with mixed plasmid extractions that
contained both correctly-recombined PGK-EM7/pACN plasmid and the non-recombined
pACN plasmid. Plasmid DNA was extracted from several of these colonies and digested
with SpeI to reveal which plasmid extractions were pure populations of the desired
pACN/PGK-EM7 plasmid.
DNA sequences homologous to specific regions of genomic Bmp2 were amplified
and ligated into pACN/PGK-EM7 (the 5′ Neo and 3′ Neo homology arms) and into
PL253 (the 5′ Bmp2 and 3′ Bmp2) in order to complete construction of the Neo minitargeting vector and the Bmp2 retrieval vector, respectively. Amplification of these
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homology arms was performed with the following settings: 94°C for 2 minutes, then 2
cycles of 94°C for 15 sec, lowest Tm of the primer pair (from the portion that binds to the
region of Bmp2) for 30 sec and 72°C for 25 sec. This was followed by 33 cycles of 94°C
for 15 sec, lowest Tm of the primer pair (including the initial non-binding region used to
insert restriction endonuclease recognition sites) for 30 sec and 72°C for 25 sec. The 5′
Neo and 3′ Neo homology arms were amplified (Invitrogen Taq DNA Polymerase kit)
using reaction mixtures containing 5 µL 10x PCR buffer minus Mg, 1 µL of 10 mM
dNTP mixture, 1.5 µL of 50 mM MgCl2, 1 µL of 10 µM forward primer, 1 µL of 10 µM
reverse primer, 2 µL of 50 ng/µL BAC DNA (RP23-384M14 from BAC-PAC), 0.3 µL of
either 5 U/µL Taq DNA Polymerase (5′ Neo arm) or 2.5 U/µL PLATINUM Pfx (3′ Neo
arm) and 38.1 µL of water. The 5′ Bmp2 and 3′ Bmp2 homology arms were amplified
(Invitrogen PLATINUM Pfx DNA Polymerase kit) using reaction mixtures containing 5
µL 10x Pfx Amplification Buffer, 1.5 µL of 10 mM dNTP, 1 µL 50 µM MgSO4, 1 µL of
10 µM forward primer, 1 µL of 10 µM reverse primer, 2 µL of 50 ng/µL BAC DNA, 0.4
µL 2.5 U/µL PLATINUM Pfx DNA Polymerase and 39.1 µL of water. To check the PCR
reactions, 5 µL of the 50-µL PCR reaction mixtures were separated on a 1% agarose gel.
The remainder of each reaction was purified using the Qiagen QIAquick PCR
Purification Kit (Qiagen,Valencia, CA) according to manufacturer’s instructions before
digesting with the appropriate restriction enzymes. The digested PCR fragments were
purified again with the PCR purification kit and were ready to be ligated.
Several steps were used to generate the Neo mini-targeting vector. Ligation of the
3′ Neo arm was accomplished using the Fermentas Rapid DNA Ligation Kit, by mixing
100 ng of pACN/PGK-EM7 digested with EcoRI, 14 ng of the 3′ Neo arm digested with
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EcoRI , 4 µL of 5x Rapid Ligation Buffer, 1 µL of 5 U/µL T4 DNA ligase and water up
to 20 µL. After 15 minutes, 5 µL of the ligation mixture was used to transform cells.
Plasmid DNA was extracted (Qiagen miniprep kit) from overnight cultures of individual
colonies and digested with EcoRI to identify plasmids with inserts. Those plasmid
preparations with inserts were then sequenced to identify correctly-orientated 3′ Neo
homology arms. Once the desired plasmid preparation was identified, it was digested
with KpnI and SalI in a step-wise manner with a purification step between each digest
(via the Qiagen QIAquick PCR Purification Kit). After the final digest, the vector was
dephosphorylated by adding 2 µL of 20 U/ µL Calf Intestinal Alkaline Phosphatase
(Promega) and 3 µL of 10 × Alkaline Phosphatase Reaction Buffer in a final volume of
30 µL. Ligation of the 5′ Neo arm was accomplished using the Fermentas Rapid DNA
Ligation Kit by mixing 100 ng of the KpnI/SalI-digested and dephosphorylated
pACN/PGK-EM7, 14 ng of the 5′ Neo arm digested with KpnI and SalI, 4 µL of 5x
Rapid Ligation Buffer, 1 µL of 5 U/µL T4 DNA ligase and water up to 20 µL. After 15
minutes, 5 µL of the ligation mixture was used to transform cells. Plasmid DNA was
extracted (Qiagen miniprep kit) from overnight cultures of individual colonies and
digested with KpnI and SalI to identify correctly-ligated and completed Neo minitargeting vectors.
The homology arms used to generate the Neo mini-targeting vector targeted the
Neo mini-targeting cassette into the 3′UTR of Bmp2, downstream of all known
posttranscriptional regulatory regions within the 3′UTR (Fritz et al., 2006; Fritz et al.,
2004).
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Bmp2 retrieval vector
Amplification and purification of the homology arms used for construction of the
Bmp2 retrieval vector are described above. The retrieval vector was constructed using the
same Fermentas Rapid DNA Ligation Kit by mixing 100 ng of PL253 (Liu et al., 2003)
digested with NotI and SpeI, 6 ng of the 5′ Bmp2 arm digested with NotI and HindIII, 6
ng of the 3′ Bmp2 arm digested with HindIII and SpeI), 4 µL of 5x rapid ligation buffer, 1
µL of 5 U/µL T4 DNA ligase and water up to 20 µL. After 15 minutes, 5 µL of the
ligation mixture was used to transform cells. Plasmid DNA was extracted (Qiagen
miniprep kit) from overnight cultures of individual colonies and digested with NotI and
SpeI to identify correctly-ligated and completed Bmp2 retrieval vectors.
Transformation of BAC into Recombinogenic Strains
E. coli strains containing the BAC with the Bmp2 gene (RP23-384M14 from
BAC-PAC) were grown overnight in 5 mL of LB broth with chloramphenicol. Cells were
transferred to a centrifuge tube and pelleted for 5 minutes at 5,000 RPM, the supernatant
removed, and the pellet dissolved in 250 µL buffer P1 (Qiagen miniprep kit) before being
transferred to an eppendorf tube. The cells were lysed by adding 250 µL P2 buffer,
mixing by inversion and incubating for 5 minutes at room temperature. The reaction was
neutralized by adding 350 µL N3 buffer, mixing by inversion and incubating on ice for 5
minutes. The supernatant was cleared by two rounds of centrifugation at 13200 rpm for 5
minutes in a tabletop centrifuge, transferring to a clean tube between centrifugation steps.
BAC DNA was precipitated by adding 750 µL isopropanol and incubating on ice for 10
minutes before being pelleted by centrifugation for 10 minutes at 13000 rpm. The pellet
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was washed with 70% ethanol and air-dried before dissolving in 50 µL TE. For
electroporation, 1 µg was used.
To make the SW102 cells electrocompetent, they were grown in a 5 mL of LB
broth with tetracycline at 32°C overnight with shaking. The next day the cells were
collected by centrifuging at 5000 rpm for 5 minutes at 0°C. Cell pellets were resuspended
in 1 mL ice-cold water. Cells were transferred to a pre-chilled 1.7-mL eppendorf tube and
centrifuged using a benchtop centrifuge for 15-20 sec at room temperature. The tubes
were placed on ice, and the supernatants were aspirated. This washing step was repeated
two more times. Finally, the cell pellet was resuspended in 40 µL ice-cold water and 1 µg
of BAC DNA was added and mixed before transferring to a pre-chilled electroporation
cuvette (0.1-cm gap). Electroporation was performed using a BIO-RAD electroporator
under the following conditions: 1.8 kV, 25 µF with the pulse controller set at 200 Ω. The
time constant was usually between 3.8 and 4.8. Following electroporation, 1 mL of LB
was added to each cuvette and the cells were transferred to a 14-mL round-bottom culture
tube and incubated with shaking for 1 hour at 32°C. SW102 cells containing the BAC
were selected for by growing on LB plates with both chloramphenicol (for the BAC) and
tetracycline (for the SW102 cells).
Mutating the bipartite NLS of Bmp2
In order to mutate the bipartite NLS of Bmp2, the galK positive/negative selection
system was used to first replace the target amino acids with the galK gene, and then
replace the galK gene with the desired mutation (KREKRQAKHKQRKRLKS was
changed to KREKRQAKHKQAAALKS) as described in Warming et al (Warming et al.,
2005). The SW102 strain used for recombineering contains a fully functional galactose
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operon except the galactokinase gene (galK) has been deleted. The galK function can be
added in trans, so the ability to grow on galactose as the sole carbon source can be
selected. Conveniently, galK can also be selected against by using 2-deoxy-galactose
(DOG); when phosphorylated by galK, DOG becomes cytotoxic. To mutate the RKR
portion of the NLS to AAA, the galK gene was amplified using primers that contain 50
bp of homology to the area directly surrounding the codons that code for the RKR.
SW102 cells containing the BAC were induced for recombination and electroporated
with the galK amplicon, and recombinant bacteria were able to grow on minimal media
with galactose as its only carbon source.
In detail, em7-galK was PCR amplified from 2 ng pgalK (Warming et al., 2005)
as template with the following cycle parameters: 94°C for 2 min, then 35 cycles of 94°C
for 15 sec, 60°C for 30 sec, and 68°C for 1.2 min. PCR was carried out (Invitrogen
PLATINUM Pfx DNA Polymerase kit) with reaction mixtures containing 5 µL 10x Pfx
Amplification Buffer, 1.5 µL of 10 mM dNTP, 1 µL 50 µM MgSO4, 1 µL of 10 µM
forward primer, 1 µL of 10 µM reverse primer, 1 µL of 2 ng/µL pgalK DNA, 0.4 µL 2.5
U/µL PLATINUM Pfx DNA Polymerase and 39.1 µL of water. After the PCR was
complete, 10 U of DpnI was added to the reaction and incubated at 37°C for 1 hour to
remove template DNA. After digestion, the reaction was separated overnight on a 1%
agarose gel. After extraction from the gel using the Qiagen Qiaex II kit according to
manufacturer’s instructions, the samples were pooled and ethanol precipitated using 0.2
M NaCl and 10 mM MgCl2.
Meanwhile, SW102 cells containing the BAC were inoculated into 5 mL of LB
broth and grown at 32°C overnight with tetracycline. The next day, 500 µL of the
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overnight culture was inoculated into 25 mL of LB with tetracycline and grown until
OD600 = 0.550. Half of the culture was kept at 32°C, while the other half was induced for
recombination by incubating for 15 minutes at 42°C. To make the cells electrocompetent,
both flasks were transferred to an ice bath and incubated for 15 minutes before pelleting
at 4000 rpm for 5 minutes at 0°C. The cells were then resuspended in 1 mL ice-cold
water and transferred to cold eppendorf tubes and washed as described above.
Electroporation was carried out using 330 ng of the purified galK gene. After a 1-hour
recovery in 1 mL of LB, the bacteria were washed twice in 1×M9 salts as follows: the
cells were pelleted in an eppendorf tube at 13200 rpm for 15 sec. and the supernatant was
removed with a pipette. The pellet was gently resuspended in 1 mL 1×M9 salts and
pelleted again. The cells were washed and resuspended in 1×M9 once more before
plating 200 µL onto M63 minimal media plates (appendix). After a 3-day incubation at
32°C, several colonies were streaked for isolation onto MacConkey indicator plates
containing chloramphenicol and tetracycline to reveal colonies capable of fermenting
galactose. The next day, several of the bright pink colonies were grown overnight in
culture. After extracting BAC DNA, PCR was used to determine if galK had recombined
into the desired location using primers that flank the NLS. If galK has inserted at the
NLS, the amplicon would be ~2.6 kb; if galK had not inserted into the proper location,
the amplicon would only be ~1.4 kb. All bright pink colonies contained successful
recombinants of galK into the desired location of Bmp2.
Double-stranded oligos were used to replace galK with the desired mutation
(KREKRQAKHKQRKRLKS to KREKRQAKHKQAAALKS). These oligos were 100bp long and contained nucleotides coding for the desired NLS mutations (three Ala
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codons) along with homology to the surrounding sequence in Bmp2. They were
purchased (Invitrogen, Carlsbad, CA), resuspended in TNE, boiled for 10 minutes, and
then slowly cooled to room temperature for 2 hours before EtOH-precipitating in the
presence of 0.2 M NaCl and 10 mM MgCl2. The oligos were resuspended in water. Cells
containing the galK BAC were grown and induced as described above and electroporated
with 300 ng of the double-stranded oligos. This time the cells were recovered in 10 mL
LB in a 50 mL Erlenmeyer flask for 4.5 hours to allow ample time to obtain cells
containing the targeted BAC only. After this recovery period, the cells were pelleted,
washed twice in 1×M9 salts, and resuspended in 1 mL of 1×M9 before plating 200 µL of
both the induced and uninduced onto M63 minimal plates containing glycerol and 2deoxy-D-galactose. The 2-deoxy-D-galactose is cytotoxic to cells that still contained the
galK gene, while those cells that had substituted the NLS mutation for the galK gene
were able to grow.
Retrieving NLSmBmp2 from the BAC
The Bmp2 retrieval vector described above was used to subclone the NLSmBmp2
gene from the BAC into pBluescript modified to contain a thymidine kinase (MC1TK)
gene. To prepare the retrieval vector for gap-repair (retrieval), 250 ng was digested with
20 units HindIII in 35 µL volume for 2 hours. The digestion reaction was run overnight
on a 1% agarose gel at 35 volts. The linearized plasmid was then excised from the gel and
purified using the Qiagen Qiaex II DNA extraction kit according to manufacturer’s
instructions.
SW102 cells containing the NLSmBmp2 BAC were grown in 5 mL of LB broth
containing chloramphenicol and tetracycline at 32°C overnight with shaking. The next
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day, 1.0 mL of the overnight culture was transferred to 20 mL of LB containing
chloramphenicol and tetracycline and incubated at 32°C with shaking until OD600 = 0.5.
Next, 10 mL of the cells were transferred to a new flask and shaken in a 42°C water bath
for 15 minutes to induce recombination while the remaining 10 mL of cells continued to
be incubated at 32°C. Both flasks of cells were promptly placed into an ice bath and
shaken to ensure rapid dropping of the temperature.
The cells were made electro-competent as described above. The cell pellet was
resuspended in 40 µL ice-cold water before 2 µL (40 ng) of the purified, linearized
plasmid was added. The cells were then electroporated and plated on LB + ampicillin
plates.
Targeting with the Neo cassette
The NLSmBmp2 retrieved plasmid was transferred into fresh (never been induced)
SW102 cells using 5 ng of DNA and plating 100 µL of the transformation reaction.
Overnight cultures were examined with a BglII digest and “genotyped” (see below) to
verify that they contained the correct plasmid. These cells were grown, induced for
recombination, and made electrocompetent as described above. The cells were
electroporated with 500 ng of the Neo mini-targeting cassette. This cassette was PCRamplified from the Neo mini-targeting vector using the 5′ Neo Forward and the
Minitargvec Reverse primers and prepared for recombination as follows. After PCR, the
mini-targeting vector template was removed with DpnI, and the cassette was
electrophoretically separated. The cassette was extracted from the gel using the Qiagen
Qiaex II gel extraction kit and EtOH-precipitated before using for electroporation.
Several PCR reactions were performed and pooled after extracting from the gel and
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before precipitating to obtain a high concentration of the Neo mini-targeting cassette.
After electroporation and a 1-hour recovery, the cells were grown on plates containing 25
ng/µL kanamyacin. Only three colonies grew, and only two of those colonies were able to
grow in culture overnight in the presence of 20 ng/µL kanamycin. Both of these colonies
contained a mixture of recombined and un-recombined plasmids, as verified through a
BglII digest and a ClaI digest.
To separate recombined clones from the un-recombined, the mixed plasmid
preparation was re-transformed into SW102 cells. No colonies were obtained until 10 ng
of DNA was used and the entire reaction was plated onto kanamycin plates. Nine
colonies were examined with a BglII digest, and six of them had only the desired,
targeted plasmid. This was confirmed by performing two more analytical digests, one
with XbaI and one with PstI and “genotyping” (see below) the plasmid to verify the
presence of the NLS mutation.

Gene Targeting in Mouse ES cells
To generate targeted mouse ES cells, two reactions of 7 ×106 129XI/SvJ-derived
AV3 ES cells were electroporated at 250 V with 40 µg of the NotI-linearized nBmp2-ko
targeting vector each. After electroporation the cuvettes were placed on ice for 20
minutes. As a negative control, 7 ×106 AV3 ES cells were also treated with the
electroporation procedure. The contents of each cuvette was then plated onto two 10-cm
dishes with mitomycinC-treated (mitoC-treated) Neor mouse embryonic fibroblasts
(MEFSs) and grown in complete media for 24 hours, at which time the media was
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removed and replaced with media containing 300 µg/mL of G418 and 2 µM FIAU
(appendix). The media was changed every other day.
Within 7-9 days, all the neomycin-sensitive (Neos) colonies had cleared and the
Neor colonies could be picked. Healthy-looking, refractile colonies were picked with a
pipette and placed into wells of a 48-well plate containing 100 µL typsin/EDTA in each
well. Once 48 colonies had been picked, the plate was placed at 37°C for 10 minutes.
Then, 100 µL ES media (appendix) (with G418 but not FIAU from this point on) was
added to all the wells to inactivate the trypsin. The cells in each well were dispersed with
a multi-channel pipetman and transferred to a 48-well plate of mitoC-treated Neor
MEFSs. Enough colonies to fill two 48-well plates of mitoC-treated Neor MEFSs were
picked from each plate. The media was changed every other day until the wells needed to
be replica-plated, which took anywhere from 1 day to 1 week depending on the well.
To replica plate, the media was removed and the desired wells were washed with
PBS before adding 100 µL trypsin/EDTA and incubating at 37°C for 10 minutes. Then,
100 µL of ES media was added to the wells and the cells were dispersed with a pipteman.
The contents of the well was then split 1:1 into wells of a 48-well plate with mitoCtreated MEFs (the master plate) and the remaining 100 µL to a 48-well plate without
MEFs (the DNA plate), both with ES media.
When the master plate had grown to confluency, the wells were rinsed with PBS,
incubated with 100 µL trypsin/EDTA at 37°C for 10 minutes, and dispersed with 100 µL
ES media before adding 200 µL of 2 × freezing media (appendix) to the wells and
swirling to mix. The plate was then wrapped in parafilm and placed in a Styrofoam box at
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-80°C. Alternatively, if wells remained that were not ready to freeze, the wells needing to
be frozen were transferred to a new 48-well plate and labeled before freezing.
When wells of the DNA plate had grown to maximum confluency they were lysed
with 300 µL Lysis Buffer and 1 mg/mL Proteinase K overnight at 37°C. To purify the
DNA, the lysate was transferred to an eppendorf tube the following day and an equal
volume of phenol:chloroform:isoamyl alcohol (24:24:1) was added. The tubes were
shaken for approximately 1 minute and then centrifuged for 4 minutes. The aqueous layer
was transferred to a new tube containing 1.2 mL of isopropanol and the tubes were
shaken again. The DNA was spooled with a fired capillary tube, dipped into 80% EtOH,
and placed into a new eppendorf tube. After the EtOH had evaporated, 50 µL TE was
added and the DNA was allowed to dissolve for several hours before removing the fired
glass capillary tube. The DNA was incubated at 37°C overnight to completely dissolve.
Additionally, collaboration with Dr. Mario Capecchi at the University of Utah is
underway to generate nBmp2-ko mice by microinjecting targeted ES cells into blastulastage host embryos. For this technique, the targeting vector was electroporated into
mouse 129/Bl6 G4-56 ES cells and DNA was isolated as explained above and analyzed
by Southern blot as detailed below.

Southern Blot Analysis
Successfully targeted loci should contain an additional DrdI site such that upon
digestion and Southern blot analysis, a 6.1-kb band would be apparent rather than the wt13.6 kb band (Fig. 12). Once the DNA had completely dissolved, a digestion reaction was
set up with 25 µL of ES DNA, 19 µL water, 5 µL of 10 × buffer 4, and 1 µL (5 units)
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DrdI (New England Biolabs, Ipswich, MA). The reaction was incubated overnight at
37°C. The following morning, an additional 1 µL of DrdI was added to the reaction and
allowed to incubate for at least 1 hour more. The digested DNA was then separated on a
0.7% TAE agarose gel at approximately 60 V for 4-5 hours. After electrophoresis, the
DNA was depurinated by soaking the gel in 0.2 N HCl for 30 minutes, rinsed in water,
and then denatured by soaking the gel for 30 minutes in 1.5 M NaCl/0.5 N NaOH. After
these treatments, the gel was neutralized by soaking in 1.5 M NaCl /0.5 M Tris-HCl, pH
7.0 for 45 minutes.
After these treatments, the DNA was transferred to a nylon membrane using the
capillary transfer method. The membrane was pre-wet in water and then soaked in 10 ×
SSC (1.5 M NaCl, 0.15 M NaCitrate ,pH 7.0) for 5 minutes. The transfer was set up as
follows, from bottom to top: a large sponge soaking in 10 × SSC, 2 pieces of Whatman
paper, the gel, the membrane, 2 more pieces of Whatman paper cut to the size of the gel,
6 cm of paper towels cut to the size of the gel, and a weight. The transfer proceeded
overnight. The following day, the membrane was rinsed in 5 × SSC for 5 minutes and
then baked at 80°C for 2 hours before a pre-hybridization incubation with Hybrisol
(Chemicon, Temecula, CA) for 1 hour at 42°C.
The 3′ flanking Bmp2 southern probe was made by PCR amplification of a region
outside of the targeting vector but contained within the fragment created by DrdI
digestion. The primers used were Bmp2southFor:
gccctctcgagCTCAATAGCTCTGGGCCTTG and Bmp2southRev:
ttatagcggccgcATCTCAGCATGGAGCCTGTC. These primers amplified a 720-bp region

and contained a XhoI and a NotI restriction site that were used to clone the amplicon into
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pBS SK+. Before labeling, these enzymes were also used to remove the probe from the
plasmid backbone. The digestion reaction was separated by gel electrophoresis and the
probe was gel-purified using the Qiagne Qiaex II gel extraction kit. The Roche
hexanucleotide labeling mix was used to label the probe according to manufacturer’s
protocol (Roche, Indianapolis, IN). Briefly, 80 ng of the purified, linearized DNA in 9 µL
total volume was boiled for 10 minutes and then placed into an ice water bath for an
additional 10 minutes. Once cooled, 3 µL 0.5 mM dNTP mix (minus dCTP) and 2 µL
Hexanucleotide mix were added to the reaction, followed by the addition of 50 µCi α-32P
dCTP and 1 µL Klenow fragment. The reaction was then incubated for 40 to 90 minutes
before stopping the reaction with the addition of 2 µL 0.2 M EDTA.
Next, the unincorporated labeled nucleotides were purified from the labeled probe
using Roche Quick Spin columns as follows. The buffer in the columns was drained by
gravity flow before centrifugation at 1100 × g for 2 minutes in a swinging-bucket rotor.
The labeling reaction was brought up to a total volume of 60 µL with water and added to
the column. The labeled probe was eluted by centrifugation at 1100 × g for 4 minutes and
then a 2 µL sample was counted with a scintillation counter. The appropriate volume of
labeled probe was boiled for 10 minutes, placed on ice for 5 minutes, and then added to
the hybridization canister already containing the membrane(s) and Hybrisol. A total of 28 ×106 cpm/mL was used for the Southern blots.
After an overnight hybridization, the membranes were washed at 55°C as follows:
5 minutes and then 30 minutes in 2 × SSC, 2% SDS followed by two 15-minute washes
in 1 × SSC, 2% SDS. The membrane(s) were then sandwiched between layers of plastic
wrap and placed in an audoradiography cassette with film.
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Thawing targeted ES cells
For the AV3 cells here at BYU, when the DNA from the 48-well plates had been
screened for recombinant clones, the plates containing the targeted clones were thawed
by floating them in a 37°C water bath. When thawed, 500 µL ES media, containing
G418, was added to the appropriate well and gently mixed. This cell suspension was
centrifuged and the media was aspirated before resuspending in fresh ES media
containing G418. The cells were plated onto a 3.5-cm dish containing Mito-C treated
Neor MEFs. When confluent, this dish was split onto a 6-cm dish and a 3.5-cm dish of
Mito-C treated Neor MEFs, plus a 3.5-cm dish without MEFs for DNA isolation to verify
the colony by repeating the Southern analysis. When confluent, the 6-cm dish and the
3.5-cm dish were split onto 6 6-cm dishes. Once the cells had reached confluency on
these plates, the cells were divided into 30 cryogenic vials and stored in a liquid N2 tank.
When the DNA plate was confluent, the DNA was isolated and analyzed via Southern
hybridization as described above.

Morulae Aggregation
Pregnant Mare Serum (PMS) and human chorionic gonadotropin (hCG) was
administered to three- to four-week-old CD1 female mice to induce superovulation
before mating with CD1 males. After two-and-one-half days (embryonic day 2.5 or E2.5)
the morulae were collected by removing the oviducts of the superovulated females and
flushing them under a dissecting microscope with a filed 30-guage needle and M2 media
(recipe in appendix). The morulae were then transferred through a series of acid tyrode
washes (Millipore, Billerica, MA) with a mouthpipette in order to remove the zona
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pellucida. Each dezoned morulae was then neutralized in M2 media and placed into a
divot in a previously-prepared tissue culture dish to await addition of ES cells.
Three days prior to the preparation of the morulae, targeted frozen transgenic
stem cells were thawed and cultured in 20% ES cell media for two days. The day before
aggregation, the cells were seeded into a new 3.5-cm dish and allowed to grow overnight.
On the day of aggregation, the cells were subjected to a light trypsin treatment in order to
allow removal from the dish while maintaining a degree of cohesion between cells.
Clusters of 4 to 12 ES cells were added to each divot containing a prepared morula. After
incubating overnight at 37°C, the ES cells and the morulae that had merged were
implanted into a pseudo-impregnated female. These Swiss Webster (SW) surrogate
mothers were mated with vasectomized SW males two-and-one-half days previous to
implantation in order to induce a state of pseudo-pregnancy. Chimeric embryos were
surgically implanted into uterine horns of the pseudo-pregnant females.

Generation of nBmp2-ko mice
It was determined that the AV3 ES cells used for gene targeting here at BYU
were not suitable for use in the morulae aggregation procedure. Consequently, we
collaborated with Dr. Mario Capecchi at the University of Utah to target 129/Bl6 G4-56
ES cells and use them for microinjection into Bl6 host embryos in order to generate
chimeric mice. Fifteen chimeras were born, all of which were substantially (over 80%)
composed of cells that derived from the targeted ES cells. When the chimeric mice have
reached sexual maturity, the males will be intercrossed with Bl6 females. The chimeric
animals are composed of cells both from the F1 host embryos from a Bl6 × CBA cross
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and the agouti ES cells. Thus, the resulting embryos will be fertilized from sperm derived
from either the host embryo or the targeted stem cell line. As the stem cells are
heterozygous for the Bmp2 allele, 50% of the progeny will carry the modified Bmp2
allele whereas 50% will be wild type. Since black G4 ES cells were used for targeting,
the black pups should also be checked. Excision of the Neo cassette will take place in the
heterozygous males as the testes specific promoter is activated and the Cre recombinase
is expressed. Intercrossing heterozygous mice will generate mice homozygous for the
nBmp2-ko allele at 25% frequency.

Genotyping
A PCR/restriction digest assay will be used to genotype the nBmp2-ko mice. PCR
on genomic DNA using the NLSmutgenotypingFor (GGCCCATTTAGAGGAGAACC)
and NLSmutgenotypingRev (CATGCCTTAGGGATTTTGGA) primers will generate a
390 bp amplicon. Amplicons containing the KREKRQAKHKQRKRLKS to
KREKRQAKHKQAAALKS mutation will contain a Cfr12I restriction site and will be
subsequently cut into 209-bp and 180-bp fragments. The following parameters have
worked well for this assay in genotyping ES cells.
The 390-bp genotyping amplicon was amplified (Invitrogen PLATINUM Pfx
DNA Polymerase kit) using reaction mixtures containing 5 µL 10x Pfx Amplification
Buffer, 1.5 µL of 10 mM dNTP mix, 1 µL 50 µM MgSO4, 1 µL of 10 µM
NLSmutgenotypingFor primer, 1 µL of 10 µM NLSmutgenotypingRev primer, 2 µL of
purified genomic DNA, 0.5 µL 2.5 U/µL PLATINUM Pfx DNA Polymerase and 38 µL
of nanopure water. The following cycling parameters were followed: 94°C for 5 minutes,
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then 34 cycles of 94°C for 25 sec, 55°C for 30 sec, and 68°C for 30 sec. After completion
of the PCR reaction, 1 µL (10 units) of Cfr12I (Fermentas, Hanover, MD) was added
directly to the reaction and incubated at 37°C for 1 hour. Following this digestion
reaction, the DNA was fractionated on a 1% agarose TBE gel. Using the O’GeneRuler 50
bp DNA Ladder (Fermentas, Hanover, MD) as a reference makes it easy to distinguish
between the mutant 209/180-bp band and the wild-type 390-bp band.

Zebrafish
We chose to use morpholinos to block translation of nBmp2. When base paired at
the translational start site, morpholinos prevent initiation of translation. When annealed to
mRNA more than 30 bases downstream of the start site, however, the morpholinos are
displaced by the ribosome and have no effect on translation (Gene Tools, LLC Targeting
Guidelines, http://www.gene-tools.com/node/18). This means that a morpholino targeted
to the downstream alternative start codon of Bmp2 will decrease production of the
cytoplasmically-translated nuclear variant without affecting translation at the upstream
start codon that produces secreted Bmp2.
All experiments were performed in wild-type zebrafish embryos (Tubingen AB)
raised at the University of Utah Centralized Zebrafish Animal Resource Center (CZAR)
and in collaboration with Dr. Richard Dorsky. We designed a morpholino antisense
oligonucleotide (MO, Gene Tools, LLC) directed against the sequence around the
putative alternative start codon of zebrafish bmp4 to block translation of zebrafish nbmp4
(nBmp4-MO): 5′-TGGGACGCCTTTGCAGGCCAAACAT-3′. A standard control MO was
also used for injections: 5′-CCTCTTACCTCAGTTACAATTTATA-3′. The MOs were
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resuspended in Danieau’s buffer (58 mM NaCl, 0.7 mM KCl, 0.4 M MgSO4, 0.6 mM
Ca(NO3)2, 0.5 mM HEPES, pH 7.6) and diluted to 2 mg/mL for injections. The MOs
were injected at the single-cell stage and embryos were allowed to develop until hatching.
Phenotypes were examined throughout development using a dissecting microscope.

In vitro transcription/translation of zebrafish bmp4
To test the specificity of our morpholino, nBmp4-MO, in vitro we constructed
zebrafish bmp4 expression vectors and used them for in vitro transcription/translation
experiments. To construct these plasmids, RNA was extracted from wild-type zebrafish
by homogenizing embryos in TRIzol (Invitrogen, Carlsbad, CA) with 10-15 passes
through a 22-guage needle. A chloroform extraction was performed by adding an equal
volume of chloroform, vortexing briefly, incubating at room temperature for 10 minutes,
and centrifuging at 11500 × g for 15 minutes at 4°C. The aqueous layer was put in a new
tube and an equal volume of isoproanol was added. After a 10 minute room-temperature
incubation, the RNA was collected by centrifugation at 11500 rcf for 10 minutes at 4°C.
After washing with 75% EtOH, the RNA was further purified by using the Qiagen
RNeasy Kit according to the manufacturer’s protocol.
To construct the expression vectors, the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA) was used for reverse transcription of bmp4 according to manufacturer’s
protocol. The cDNA was used for PCR amplification of full-length bmp4 and a nuclearonly version of bmp4 that started at the downstream ATG. Primers were used that would
include a BamHI and a XhoI restriction site at either end of the amplicons for cloning into
pCS2p+ (Richard Dorsky, University of Utah).
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Zebrafish bmp4 protein was synthesized in vitro with the incorporation of
[35S]methionine employing the TNT Coupled Wheat Germ Extract System (Promega,
Madison, WI) according to manufacturer’s instruction. To test the specificity of the
nBmp4-MO, 10 µg was included in some reactions. In order to visualize the products, 7
µL of the reaction was boiled for 5 minutes with 20 µL 2× Laemmli Sample Buffer and
5% β-mercaptoethanol before separating by SDS-PAGE and visualizing by
autoradiography.

RESULTS
Nuclear Localization of putative NLS/GFP fusion constructs
We first gained interest in nuclear Bmp2 when it emerged as a possible DNAbinding protein from two separate experiments routinely performed in our lab to identify
possible transcription factors for cartilage-specific collagen genes: the yeast one-hybrid
screen and DNA affinity chromatography followed by mass spectrometry. Having this
secreted protein identified as a possible DNA-binding protein in two separate assays led
us to analyze its amino acid sequence in search of NLSs. Indeed, analysis of the Bmp2
amino acid sequence using the PSORT II program identified three potential NLSs. NLSa
(PELGRKK) and NLSb (PLHKREK) are monopartite signals located within the
propeptide region, NLSa at the N-terminal end and NLSb at the C-terminal end. NLSc
(KREKRQAKHKQRKRLKS) is a bipartite NLS that spans the site of proteolytic
cleavage between the propeptide and mature peptide (Fig. 1).
To test the functionality of each of the putative NLSs identified by PSORT II,
each was fused to the C-terminal end of green fluorescent protein (GFP) to determine
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Figure 1. Schematic of the Bmp2 preproprotein. Map of the rat Bmp2 preproprotein
showing the signal peptide, propeptide, and mature chain. The amino acid sequence and
location of each predicted NLS is underlined, and the site of proteolytic cleavage is
marked by an arrow. Critical amino acids in the bipartite NLS are shown in bold.
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whether the NLS could direct GFP to the nucleus. The fusion constructs were transiently
transfected into rat chondrosarcoma (RCS) cells, and cells were stained with the DNAspecific stain TO-PRO-3 iodide to visualize nuclei. Neither NLSa (PELGRKK) nor
NLSb (PLHKREK) produced nuclear localization of GFP. Rather, GFP (a 26-kDa
protein) fused to the short NLSs was distributed throughout both the cytoplasm and the
nucleus as would be expected for a protein that is small enough (<30-40 kDa) to diffuse
through nuclear pores (Adam, 2001; Cubitt et al., 1995) (Fig. 2A).
Because the two short putative NLSs bracket the free propeptide that would be
released upon proteolytic cleavage of the Bmp2 proprotein, we investigated whether the
two NLSs might cooperate to transport the free propeptide to the nucleus. We built a
construct in which the N-terminal putative NLSa was fused to the N-terminus of GFP and
the C-terminal putative NLSb was fused to the C-terminus of GFP. Transient transfection
of this construct into RCS cells revealed that even together, the two short NLSs failed to
produce nuclear localization of GFP (Fig. 2A).
Finally, the putative bipartite NLSc, also containing three of the amino acids of
NLSb -PLHKREKRQAKHKQRKRLKS, was fused to the C-terminus of GFP. Transient
transfection of this expression plasmid into RCS cells produced clear and unmistakable
nuclear localization of GFP, indicating that the predicted bipartite NLSc is indeed
functional (Fig. 2A).
To determine whether the intact bipartite NLS was functional in the context of the
entire Bmp2 proprotein we built another fusion construct, this time designed to express
the entire Bmp2 proprotein, including the signal peptide, with GFP fused to its Cterminus. Transient transfection of this wtBmp2/GFP plasmid into RCS cells produced
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Figure 2. Bmp2 contains a functional bipartite NLS that overlaps the site of
proteolytic processing. (A) To test the ability of each predicted NLS to direct GFP to
the nucleus, GFP/NLS fusion constructs were built. These expression vectors were
transfected into RCS cells, and GFP localization (green) was visualized using laser
confocal microscopy. Nuclei were stained with TO-PRO-3 (red). Neither NLSa nor
NLSb directed nuclear localization, even when one was fused to each end of GFP
(NLSa/b). Instead, GFP diffused throughout the cytoplasm and nucleus. The bipartite
NLSc, in contrast, directed strong nuclear localization. To determine whether the
bipartite NLSc is functional within Bmp2, GFP was fused to the C-terminus of the fulllength Bmp2 preproprotein (wtBmp2/GFP). In a parallel fusion construct, the bipartite
NLSc was mutated (NLSmBmp2/GFP) (KREKRQAKHKQRKRLKS was changed to
AAEKRQAKHKQAAALKS). Representative images are shown. (B) The wild-type
fusion construct produced nuclear localization of Bmp2/GFP in 21% ± 3% of transfected
cells, while a series of mutations within the bipartite NLSc eliminated nuclear
localization. (C) Alignment of Bmp2 bipartite NLSc sequences from six different
species. The conserved six basic amino acids that characterize this sequence as a
bipartite NLS are in bold. Danio rerio bmp4 was used for alignment.

42

striking and unambiguous nuclear localization of the fusion protein in approximately
21% ± 3% of transfected cells, sometimes with areas of high concentration within the
nucleus (Fig. 2A). A control expression plasmid expressing GFP only produced diffuse
GFP in both the cytoplasm and nucleus of all transfected cells as previously observed by
others (Cubitt et al., 1995), verifying that the Bmp2 portion of the fusion protein was
required for nuclear localization.

The bipartite NLS is necessary for nuclear localization of Bmp2/GFP
A series of mutations was introduced into the bipartite NLS within the Bmp2/GFP
fusion construct to investigate whether the bipartite NLS is the only sequence involved in
the nuclear translocation of proBmp2 (KREKRQAKHKQRKRLKS changed to
KREKRQAKHKQAAALKS, AREKRQAKHKQAAALKS,
AREKRQAKHKQAAALAS, and AAEKRQAKHKQAAALKS) (Table 1). When
transfected into RCS cells, the NLSmtBmp2/GFP fusion constructs all produced 0%
nuclear localization of Bmp2/GFP, confirming that the bipartite NLS is sufficient and
necessary for nuclear localization and that no other sequence elements can compensate
for the absence of the bipartite signal (Fig. 2B). Alignment of the Bmp2 amino acid
sequence from six different species including Rattus norvegicus, Mus musculus, Homo
sapiens, Gallus gallus, Xenopus laevis, and Danio rerio revealed that the bipartite NLS is
highly conserved (Fig. 2C).
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Plasmid Name
1. NLSaGFP
2. NLSbGFP
3. NLSa/bGFP
4. NLScGFP
5. wtBmp2/GFP
6. KRmBmp2/GFP
7. RKRmBmp2/GFP
8. K RKRmBmp2/GFP
9. K RKR KmBmp2
/GFP
10. KR RKRmBmp2
/GFP
11. mtBmp2/GFP
12. HA-wtBmp2
13. HA-RKRmBmp2
14. ERmBmp2
15. pcDNA3.1
16. Neo mini-targeting
vector
17. Bmp2 retrieval
vector
18. pACN
19. pACN/PGK-EM7
20. RP23-384M14
21. NLSmBmp2 BAC
22. NLSmBmp2
retrieved plasmid
23. nBmp2-ko targeting
vector

Description
putative NLSa cloned C-terminal to GFP in pCMV/GFP
putative NLSb cloned C-terminal to GFP in pCMV/GFP
putative NLSa and b cloned to bracket GFP in pCMV/GFP
putative NLSc cloned C-terminal to GFP in pCMV/GFP
wtBmp2 cDNA cloned N-terminal to GFP in pcDNA3.1/CTGFP-TOPO
KREKRQAKHKQRKRLKS mutated to
AAEKRQAKHKQRKRLKS
KREKRQAKHKQRKRLKS mutated to
KREKRQAKHKQAAALKS
KREKRQAKHKQRKRLKS mutated to
AREKRQAKHKQAAALKS
KREKRQAKHKQRKRLKS mutated to
AREKRQAKHKQAAALAS
KREKRQAKHKQRKRLKS mutated to
AAEKRQAKHKQAAALKS
KREKRQAKHKQRKRLKS mutated to
KREKGQAKHKQRKRLKS
wtBmp2 cDNA cloned N-terminal to GFP in pcDNA3.1/CTGFP-TOPO
Bmp2 cDNA containing the RKR to AAA mutation with an HA
tag at the C-terminal end
Bmp2 in pcDNA3.1 with the signal peptide removed,
producing only nBmp2
vector used for expression of Bmp2; often used as a negative
control
contains the neomycin resistant cassette inserted into the
nBmp2-ko targeting vector
contains MC1TK and Bmp2 homology arms for subcloning
Bmp2 from the BAC using recombineering
contains a PolII promoter driving neo expression and a testesspecific promoter driving Cre expression
the PolII promoter has been substituted with the combined
PGK-EM7 promoter
the BAC that contains mouse Bmp2 from the Black 6 strain
Bmp2 NLS mutated to KREKRQAKHKQAAALKS in the BAC
NLSmBmp2 subcloned from the BAC into the Bmp2 retrieval
vector
finished vector containing NLSmBmp2, the Neo cassette, and
the MC1TK coding sequence

Table 1. DNA constructs used in Book I.
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Endogenous Bmp2 localizes to the nucleus
To determine if endogenous Bmp2 localized to the nucleus of cultured cells,
immunocytochemistry was performed on RCS, BALB/3T3 fibroblasts, 10T1/2
mesenchyme cells, 231 breast cancer cells, 435 breast cancer cells, MCF-7 breast cancer
cells, Hep-G2 liver cancer cells, HT29 colon cancer cells, and a primary culture of mouse
embryonic fibroblasts (MEFs). Two different anti-Bmp2 antibodies (BMP-2 (N-14):sc6895, Santa Cruz Biotechnology, Santa Cruz, CA, and Bmp2, ab14933, Abcam,
Cambridge, MA) were used to perform the immunocytochemistry and to verify that the
results were not an antibody-specific artifact. These experiments revealed that
endogenous Bmp2 was in fact localized to the nucleus in a number of tissue culture lines
and in a primary cell culture (Fig. 3A and B). Interestingly, the degree of nuclear
localization of Bmp2 was not the same in each cell line; most of the tissue lines had
distinct nuclear localizations while others, such as RCS cells, did not.

Western blot analysis reveals endogenous Bmp2 in nuclear extracts from cultured
cells
To determine the size of nBmp2, nuclear proteins were extracted from nontransfected cell lines and analyzed by western blotting using an anti-Bmp2 antibody. In
parallel, nuclear proteins were extracted from cells transfected with an HA-tagged
nBmp2 expression vector (ERmBmp2-HA) and were analyzed by western blotting using
an anti-HA antibody. Both the anti-Bmp2 and anti-HA antibodies recognized a band that
corresponds to the theoretical size of nBmp2, 38.6 kDa (Fig. 4).
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Figure 3. Immunocytochemistry reveals endogenous Bmp2 in the nuclei of cultured
cell lines. (A) Non-transfected cells were cultured on slides and immunostained using
the anti-Bmp2 antibody (BMP-2 (N-14):sc-6895, Santa Cruz Biotechnology ) (green).
Nuclei were stained with TO-PRO-3 (red), and cells were examined by laser confocal
microscopy. Many cell cultures contained cells with strong nuclear localization of Bmp2.
Staining with only the secondary antibody gave no signal, as indicated by the panels on
the right-hand side of the figure. (B) To rule out the possibility of an antibody-specific
artifact, the immunofluorescence staining was repeated using a second anti-Bmp2
antibody (Bmp2, ab14933, Abcam), and similar results were obtained.
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Figure 4. Western blot analysis reveals endogenous Bmp2 in nuclear extracts from
cultured cells. (A) Nuclear proteins were extracted from non-transfected cell lines and
analyzed by western blotting using an anti-Bmp2 antibody. (B) In parallel, nuclear
proteins were also extracted from cells transfected with ERmBmp2-HA and were
analyzed by western blot using an anti-HA antibody in order to reveal the size of nBmp2.
Both the anti-Bmp2 and anti-HA antibodies recognized a band that corresponds to the
theoretical size of nBmp2, 38.6 kDa.

48

Modulation of proteolytic processing does not alter nuclear localization of Bmp2
The cleavage site of Bmp2, R-E-K-R-↓, is a consensus site for furin as well as for
several related members of the proprotein convertase family (Granjeiro et al., 2005;
Thomas, 2002). Furin has been shown to proteolytically activate Bmp4, the Bmp family
member most closely related to Bmp2 (Mishina, 2003), but this protease has not
previously been shown to activate Bmp2 (Cui et al., 1998). To determine whether furin
can cleave Bmp2, we used an in vitro protein cleavage assay. We synthesized full length
Bmp2 from cDNA in vitro with the incorporation of 35S methionine. When separated by
SDS-PAGE, the primary protein product was a 43-kDa peptide as expected (Fig. 5A, lane
1). Incubation of the radiolabeled Bmp2 proprotein with 10 units of furin for 1 or 3 hours
caused a new peptide to appear at 31 kDa, the predicted molecular weight of the free
propeptide following proteolytic cleavage of Bmp2 (Fig. 5A, lanes 2 and 3) (the mature
Bmp2 peptide, with a predicted molecular weight of approximately 13 kDa, was not
visible because of background radioactivity in that region of the electrophoretic gel).
When furin was preincubated with the serine protease inhibitor α1-PDX, which is a
mutated form of α1-antitrypsin and highly selective in its inhibition of furin (Anderson et
al., 1993; Jean et al., 1998), formation of the 31-kDa peptide was not observed, indicating
the ability of α1-PDX to prevent cleavage of Bmp2 by furin (Fig. 5A, lane 4).
In order to examine whether furin plays a role in regulating Bmp2 nuclear
localization in vivo, we utilized an α1-PDX expression plasmid that was a kind gift from
Dr. Gary Thomas at the Oregon Health Sciences University in Portland, Oregon. We
cotransfected this plasmid with the wtBmp2/GFP fusion plasmid into RCS cells to
determine whether inhibition of furin activity could increase nuclear localization of the

49

Figure 5. Inhibition of Bmp2 proprotein processing does not increase nuclear
localization. (A) In vitro synthesis of radiolabeled Bmp2 preproprotein produced the
expected 43-kDa protein (lane 1, large arrow). Incubation of this protein with
recombinant furin for 1 or 3 hours generated a new protein band at 31 kDa, the predicted
size of the combined free Bmp2 signal peptide and propeptide following proteolytic
cleavage (lanes 2 and 3, small arrow). Preincubation of the furin with α1PDX, a serine
protease inhibitor that blocks furin activity, prevented the formation of this band (lane 4).
(B) Furin and α1PDX expression plasmids were each cotransfected with the
wtBmp2/GFP fusion plasmid into RCS cells. Increasing furin expression did not
significantly decrease nuclear localization of Bmp2/GFP (p = 0.810), nor did inhibiting
furin activity with α1PDX significantly increase nuclear localization (p = 0.145).
Mutation of the Bmp2 cleavage site to make it unrecognizable by furin or any related
proprotein convertase (mtBmp2/GFP) also failed to significantly increase nuclear
localization of Bmp2/GFP (p = 0.652).
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wtBmp2/GFP fusion protein. Transfection of the wtBmp2/GFP expression plasmid alone
resulted in nuclear localization of the fusion protein in 21% ± 3% of transfected cells. Cotransfection with the α1-PDX expression increased nuclear localization of the
wtBmp2/GFP fusion protein to 32% ±7%, but the increase was not statistically
significant (p = 0.145) (Fig. 5B). We also used a furin expression vector in a
cotransfection with the wtBmp2/GFP fusion construct to investigate whether
overexpression of furin could decrease the percentage of cells showing nuclear
localization of Bmp2. This resulted in 22% ± 5% of transfected cells showing nuclear
localization, an insignificant increase (p = 0.810) (Fig 5B).
Since it is possible that other serine proteases besides furin are involved in the
proteolytic activation of Bmp2, we constructed a cleavage mutant of Bmp2 that contained
a disrupted consensus proteolytic cleavage site (mtBmp2/GFP) but with the essential
amino acids in the bipartite NLS intact (KREKRQAKHKQRKRLKS was changed to
KREKGQAKHKQRKRLKS). This mutant could not be proteolytically processed by
any member of the proprotein convertase family. This cleavage mutant still produced
nuclear localization in 22% ± 4% of transfected cells, statistically similar to the nuclear
localization observed in wtBmp2/GFP (0.652) (Fig. 5B). In summary, neither furin
overexpression, furin inhibition, nor inactivation of the cleavage recognition sequence
produced any significant difference in the nuclear localization of Bmp2/GFP. These
results suggest that regulation of proteolytic processing of Bmp2 is probably not the
mechanism by which the uncleaved nuclear variant of Bmp2 is produced.
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Translation from an alternative, downstream start codon leads to nuclear
localization of Bmp2
The results of the cleavage experiments led us to hypothesize that Bmp2 nuclear
localization is achieved not through regulating Bmp2 proprotein processing but rather
through avoiding the secretory pathway altogether by gaining access to the cytosol for
translation. If translated via free ribosomes in the cytosol, Bmp2 would avoid contact
with proprotein convertases located in the rER and Golgi, and the Bmp2 bipartite NLS
could then be utilized for translocation to the nucleus. It would be possible for Bmp2 to
gain access to the cytosol if translation of nBmp2 occurred at an alternative start codon
downstream of the signal peptide, thereby allowing it to bypass the rER.
To investigate the possibility of an alternative Bmp2 translational start site
downstream of the signal peptide, we examined the nucleotide sequence and found an inframe ATG surrounded by a partial Kozak sequence starting at nucleotide 236. We used
the NetStart 1.0 Prediction program (http://www.cbs.dtu.dk/services/NetStart/) to
determine the likelihood that ATG-236 is a functional initiation codon. The program
rated ATG-236 with a score of 0.724, second only to the conventional initiator codon at
0.848 (Fig. 6A). In support of our hypothesis that ATG-236 is an alternative start codon,
in vitro transcribed and translated wtBmp2 in the presence of 35S-methionine produced
two major products: the full-length expected band at 43 kDa as well as a minor 37-kDa
band that is the predicted size of a protein generated from initiation at ATG-236 (Fig. 5A,
lanes 1-4).
To determine if translation initiating from ATG-236 is responsible for the 37-kDa
product, the putative alternative start codon (ATG-236) was converted to AAG to prevent
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Figure 6. Translation of Bmp2 from an alternative start codon downstream of the
signal peptide produces the uncleaved nuclear variant of Bmp2. (A) The N-terminus
of the rat Bmp2 protein with corresponding DNA sequence is shown. The conventional
start codon 1, as well as the predicted downstream alternative start codon, are marked
(►). Amino acids of the signal peptide are shown in italics. (B) In vitro synthesis of
Bmp2 produced the expected 43-kDa protein as well as some lower molecular weight
proteins (lane 1). Substitution of the predicted alternative start codon 58 (position 236 in
the mRNA) with a non-initiator AAG codon eliminated one of the smaller proteins,
indicating that this protein had been initiated at codon 58 (arrow). (C) Bmp2/GFP fusion
constructs containing ATG to AAG substitutions in either the conventional start codon 1
or the alternative start codon 58 were transfected into RCS cells to examine the effects of
these mutations on nuclear localization of Bmp2. Mutation of the conventional start
codon (conventional ATGm) to force utilization of the downstream alternative start
codon increased nuclear localization dramatically (p < 0.001), and mutation of the
alternative start codon (downstream ATGm) decreased nuclear localization by half (p =
0.014). (D) Alignment of the Bmp2 alternative start codon from six different species.
The conserved alternative start codons are indicated in bold. Danio rerio bmp4 was used
for alignment.
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its utilization (ATG-236Bmp2). The construct was then transcribed and translated in vitro
in the presence of [35S]methionine. Mutation of the putative alternative start site ATG236 abolished the 37-kDa protein product generated from wtBmp2, indicating that ATG236 is the start site from which translation of the 37-kDa protein is initiated (Fig. 6B).
To study the significance of the alternative translation initiation codons in vivo,
we mutated the conventional start codon, ATG-65, and the alternative start codon, ATG236, in the context of the wtBmp2/GFP fusion construct and transfected them into RCS
cells. The subcellular localization of GFP was analyzed by fluorescent laser confocal
microscopy as described. Mutation of ATG-65 to prevent its utilization and encourage
use of any downstream initiation codons, dramatically increased nuclear localization of
transfected cells to 91 ± 3% (Fig. 6C). In contrast, mutation of the alternative start codon
ATG-236 reduced nuclear localization to only 10% ± 1% of transfected cells (Fig. 6C).
These results demonstrate the importance of the alternative start codon ATG-236 for
synthesis of the nuclear form of Bmp2 in cultured cells. Alignment of the Bmp2 amino
acid sequence from six different species including R. norvegicus, M. musculus, H.
sapiens, G. gallus, X. laevis, and D. rerio revealed that the alternative downstream ATG
is highly conserved (Fig. 6D).

Mutating the Bmp2 bipartite NLS does not affect secretion
Having verified the existence of nBmp2 and identified a mechanism for its
localization to the nucleus, we were interested in uncovering the function of nBmp2. We
determined to generate mice that lack nBmp2 but still produce secreted Bmp2. Previous
experiments demonstrated that the bipartite NLS (KREKRQAKHKQRKRLKS), which
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spans the cleavage site, was responsible for nuclear transport of Bmp2, and thus the
amino acid alterations to generate mice lacking nBmp2 should be within this sequence.
Altering this sequence was complicated by the fact that the RKR-K portion of the NLS is
within the secreted region of Bmp2; also, the KR portion of the NLS overlaps the
recognition sequence for the proprotein convertases responsible for cleaving the Bmp2
proprotein. Changing these amino acids had the potential to alter the function of secreted
Bmp2 or to prevent processing of Bmp2, in essence creating a Bmp2 knockout mouse.
Previous experiments determined that mutating the RKR portion of the NLS
would prevent nuclear localization and data reported elsewhere suggested that this
mutation would also have minimal effect on the function of secreted Bmp2 (Hillger et al.,
2005; Ohkawara et al., 2002). We wanted to determine if mutating the RKR portion of
the Bmp2 bipartite NLS would affect the processing and secretion of Bmp2. To do this,
RCS cells were transfected with either the HA-tagged wtBmp2 (HA-wtBmp2) or RKRm
(HA-RKRmBmp2) expression plasmids and allowed to grow for two days before the
HA-tagged proteins were immunoprecipitated from the media and subjected to
immunoblotting. Both immunoprecipitation/immunoblotting reactions resulted in protein
bands slightly lower than the 20-kDa ladder band, indicating that mutating the RKR
portion of the bipartite NLS to AAA does not affect proper processing and secretion of
Bmp2 (Fig. 7A). Further supporting this visual analysis, the UN-SCAN-IT software
program was used to quantitate the relative intensity of the two bands; it determined that
the intensity of the band from HA-wtBmp2 transfected cells to be 7042 relative intensity
units while the intensity of the band from the HA-RKRmBmp2 transfected cells to be
similar at 7011 relative intensity units compared to background levels (Fig. 7B).

55

Figure 7. Mutation of the RKR portion of the bipartite NLS does not inhibit
secretion of Bmp2. (A) To determine whether mutation of the RKR portion of the
bipartite NLS (KREKRQAKHKQRKRLKS to KREKRQAKHKQAAALKS) affected
cleavage and secretion of Bmp2, the media from RCS cells transfected with either HAtagged wtBmp2 or HA-tagged RKRmBmp2 was collected. The tagged proteins were
immunoprecipitated and analyzed via western blotting using an anti-HA antibody. (B) To
quantify the band intensities from the western blot, the image was scanned and analyzed
by the UN-SCAN-IT program. The intensity of the band from the HA-wtBmp2
transfected cells was 7042 relative intensity units while the intensity of the band from the
HA-RKRmBmp2 transfected cells was similar at 7011 relative intensity units.
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Microarray and Real-Time PCR
To learn more about the function of nBmp2 in the nucleus, we determined to
perform microarray analysis. To do this, we generated a plasmid that exclusively
expresses nBmp2 by removing the signal peptide. mRNA was isolated from RCS cells
transfected with this plasmid (ERmBmp2) and from RCS cells transfected with the empty
expression vector (pcDNA3.1) for comparison. Three biological replicates were used for
the gene expression analysis by Assuragen on Affymetrix Rat 230 2.0 genomic arrays. In
addition, two of the biological replicates were also re-analyzed by GenUs Biosystems on
GE CodeLink Arrays. These analyses indicated that there were over 300 genes that had a
p-value of <0.05 and a fold-change of >1.5 fold in either direction and were considered
significant. The genes with altered expression clustered largely as genes involved with
nervous system development and function, lipid metabolism, immune system
functioning, and cancer (Table 2).
Unfortunately, a large proportion of these genes had such low initial expression
levels that even after activation, but especially after inhibition, real-time PCR could not
be performed on them accurately. As an additional control in our real-time PCR
experiments, we used RNA from cells transfected with an expression vector for nuclear
GFP. This proved to be a good control, as a few of the genes that were expressed at levels
high enough for real-time PCR analysis had differential expression when nuclear GFP
was overexpressed. However, of the few genes with expression levels high enough for
real-time PCR, two genes, forming binding protein (Fnbp1) and neuron-glia-CAMrelated cell adhesion molecule (NrCam), appeared to respond specifically to
overexpression of nBmp2. Fnbp1 was down-regulated while NrCam was up-regulated.
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Table 2. Selected genes showing greater than 2-fold change in gene expression in
response to nBmp2.
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Construction of the nBmp2 knock-out targeting vector
The nuclear Bmp2-knockout targeting vector was constructed using
recombineering (recombination-mediated genetic engineering) (Copeland, Jenkins et al.
2001). This technique uses a modified E. coli strain containing defective λ prophage
recombination genes (strain SW102). A temperature-sensitive repressor controls the
expression of the λ recombination genes allowing for induction of recombination to occur
upon heating the cells. The steps taken to construct the targeting vector included mutating
the bipartite NLS of Bmp2 in the BAC, subcloning the mutated Bmp2 gene in to a
plasmid, and targeting this NLSmBmp2 with a modified ACN Neo selection cassette (Fig.
8).
Mutating the bipartite NLS of Bmp2
In order to mutate the bipartite NLS of Bmp2, the galK positive/negative selection
was used to first replace the target amino acids with the galK gene, and then replace the
galK gene with the desired mutation (KREKRQAKHKQRKRLKS was changed to
KREKRQAKHKQAAALKS) as described in Warming et al. PCR on BAC DNA with
the inserted galK was used to determine if galK had recombined into the desired location.
If galK had inserted at the NLS, the amplicon would be ~2.6 kb; if galK had not inserted
into the proper location, the amplicon would only be ~1.4 kb. The PCR assay revealed
that all colonies had successful recombination of galK into the desired location (Fig. 9A).
The next step was to use double-stranded oligos to replace galK with the desired
mutation. These oligos were 100-bp long and contained nucleotides coding for the
desired NLS mutations (three Ala codons) along with homology to the surrounding
sequence in Bmp2. The PCR method described above was used to determine if the galK
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Figure 8. Construction of the nBmp2-ko targeting vector using recombineering. The
bipartite NLS of Bmp2 in the BAC RP23-384M14 was mutated by using the galK
positive/negative selection scheme. The galK amplicon included 50-bp homology arms
homologous to the areas surrounding the codons that code for the RKR portion of the
NLS (indicated by black bars) and was electroporated into induced SW102 cells already
containing the BAC. Once correctly-targeted clones were identified, the galK gene was
replaced with codons for three Ala residues via recombineering. Cells still containing the
galK gene were selected against by using 2-deoxy-galactose. Using recombineering, the
Bmp2 gene that carried the mutated NLS was subcloned into a plasmid containing
MC1TK using recombineering. The 300-bp homology arms used for this step are
indicated as red and blue boxes. The final step replaced the PolII promoter from the ACN
Neo cassette with a dual prokaryotic-eukaryotic promoter PGK-EM7 so the Neo gene
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would also be expressed in E. coli. This Neo mini-targeting vector was then recombined
into the Bmp2 gene using homology arms indicated with green and pink boxes to produce
the completed targeting vector.
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gene had successfully been replaced during recombineering. Of the 10 colonies that were
grown in overnight culture from this plate, all no longer contained the galK gene (Fig.
9B). All 10 also contained the desired NLSm sequence as determined by sequencing (Fig.
9C).
Retrieving NLSm Bmp2 from the BAC
In order to subclone the mutated Bmp2 gene from the BAC into a plasmid, cells
containing the NLSm BAC were grown, induced for recombination, and electroporated
with 40 ng of the linearized Bmp2 retrieval vector containing the appropriate homology
arms and MC1TK. The following day, the ratio of colonies on the induced plate compared
to the control (uninduced) plate was large, indicating that recombination had occurred as
expected. Plasmid DNA was extracted from overnight cultures of individual colonies
from the induced plate and digested with BglII to identify correctly-recombined plasmids.
Of the eight colonies examined, three contained the appropriate bands for the NLSm
Bmp2 retrieved plasmid: 5137 bp, 3575 bp, 2603 bp, 1927 bp, 1853 bp, 986 bp, 425 bp,
and 390 bp (Fig. 10). Sequencing of the NLS region verified that these plasmids were
indeed correct.
Targeting with Neo cassette
The final step in constructing the nBmp2-ko targeting vector was to insert the
neomycin selection cassette into the Bmp2 gene in the area that would be the 3′UTR of
Bmp2 after transcription. Cells containing the retrieved NLSm Bmp2 plasmid were
grown, induced for recombination, and electroporated with the Neo mini-targeting
cassette. Only three colonies grew, and only two of those colonies were able to grow in
culture overnight in the presence of 20 ng/µL kanamycin. After extracting the plasmids
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Figure 9. The bipartite NLS of Bmp2 in BAC RP23-384M14 was mutated.
Recombineering was used to replace the nucleotides coding for the RKR portion of the
bipartite NLS with the galk gene, and then to replace the galk gene with the nucleotides
coding for the three Ala residues (KREKRQAKHKQRKRLKS to
KREKRQAKHKQAAALKS). (A, B) Using primers that flank the bipartite NLS, PCR
was used to determine if the galk gene was present within that region. (A) galk had
successfully recombined into the bipartite NLS, yielding a 2.6 kb amplicon. (B) After the
recombineering reaction to replace the galk gene with the desired mutation had been
performed, PCR was again used to verify that galk was no longer present, as indicated by
the presence of the 1.4 kb band. (C) Sequencing verified that the nucleotides coding for
RKR had in fact been exchanged for nucleotides coding for AAA.
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Figure 10. NLSmBmp2 was subcloned from the BAC into a plasmid. After the
recombineering reaction to subclone the mutated Bmp2 from the BAC into the retrieval
vector containing the MC1TK gene, eight plasmid preparations were digested with BglII.
NLSmBmp2 was successfully recombined into the retrieval vector in three of the plasmid
preparations as indicated by the presence of the following bands: 5137 bp, 3575bp, 2603
bp, 1927 bp, 1853 bp, 986 bp, 452 bp, and 390 bp.
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from the colonies, they were digested with BglII. A correctly-targeted plasmid would
give the following bands: 5137 bp, 4472 bp, 3575 bp, 1927 bp, 1853 bp, 1742 bp, 986 bp,
425 bp, and 390 bp. The NLSm Bmp2 retrieved plasmid would not have the 4472-bp
band nor the 1742-bp band but an additional band of 2603 bp (Fig. 11C ). Digestion of
both of the colonies revealed that they contained a mixture of recombined and unrecombined plasmids since all bands were present (Fig. 11A). To verify this result, the
colonies were also digested with ClaI. A correctly-targeted plasmid would give the
following bands: 10021 bp, 3713 bp, 3213 bp, 1961 bp, and 1599 bp. The untargeted
NLSmBmp2 retrieved plasmid would only have a 10021-bp band and a 6815-bp band
(Fig. 11C). Again, digestion of both of the colonies revealed that they contained a
mixture of recombined and un-recombined plasmids since all bands were present (Fig.
11A).
To separate recombined clones from the un-recombined, the mixed plasmid
preparations were re-transformed into SW102 cells. No colonies were obtained until 10
ng of DNA was used and the entire reaction was plated onto kanamycin plates. Nine
colonies were examined with a BglII digest, and six of them had only the desired,
targeted plasmid. This was confirmed by performing two more analytical digests, one
with XbaI and one with PstI and genotyping the plasmid as described (Fig. 11B).

Southern blot analysis identifies correctly targeted ES cells
The completed nBmp2-ko targeting vector was linearized and electroporated into
AV3 ES cells. After selection with G418 and FIAU, the resistant colonies were analyzed
by Southern hybridization to identify targeted clones. Successfully targeted loci would
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Figure 11. Completion of the nBmp2-ko targeting vector. The final step in
construction of the nBmp2-ko targeting vector was to target the neomycin selection
cassette into the area that would be the 3’UTR of Bmp2 after transcription. (A) After the
recombination reaction, plasmid DNA was extracted and digested with either BglII or
ClaI. These digests revealed that the plasmid preparation contained a mixture of targeted
and untargeted plasmids since bands specific to either plasmid were present (see table in
(C)). (B) The mixed plasmid preparations were re-transformed, plasmid DNA was
extracted, and this time the plasmid DNA was also digested with XbaI and PstI, which
revealed that the desired, targeted plasmid had been isolated (see table in (C)). (C) Table
indicating the bands that would be present from the targeted or untargeted plasmids after
each digestion.
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now contain an additional DrdI site such that upon digestion and Southern blot analysis, a
6.1-kb band would be apparent rather than the wt-13.6 kb band (Fig. 12A). There were
204 Neor-ES clones to screen for recombinant clones via Southern hybridization. Of
these, 4 contained a targeted Bmp2 locus as verified by the presence of both the 13.6-kb
wild-type band and the 6.1-kb targeted-allele band (Fig.12B). Since the 129/Bl6 G4-56
ES cells from Dr. Mario Capecchi’s lab were from the same genetic background as the
targeting vector (Bl6), much higher targeting efficiency was achieved: 17 out of 147
screen clones contained the targeted allele.

nBmp2-ko chimeras are successfully generated
The 1c-9 ES cells from the Capecchi lab were used for microinjection to generate
chimeric mice. Fifteen chimeras were born, 10 of which appear to be over 90% and the
remaining five appear to be over 80% composed of cells from the targeted ES cell line.

Zebrafish lacking nbmp4 have severe heart defects
To investigate the function of nBmp2 in development, we performed knockdown
experiments in zebrafish embryos. Zebrafish have three different BMP proteins, bmp2a,
bmp2b, and bmp4, which are all 60-62% homologous with rat Bmp2, complicating the
determination of which zebrafish gene should be considered the homologue of
mammalian Bmp2. Zebrafish bmp4 contains the conserved bipartite NLS overlapping the
site of proteolytic cleavage, while bmp2a and bmp2b are both missing one of the first two
basic amino acids (Fig. 13A). For this reason, we chose to design a morpholino antisense
oligonucleotide (MO) against the alternative start codon in bmp4 to block translation of
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Figure 12. Southern analysis reveals ES cells targeted with the nBmp2-ko targeting
vector. (A) Schematic of the nBmp2-ko targeting vector. The Bmp2 exons are numbered
and represented as black boxes while the Neo cassette and thymidine kinase (TK) gene
are represented as grey boxes. Insertion of the Neo cassette introduces a DrdI restriction
site as indicated. The mutation of NLSc (KREKRQAKHKQRKRLKS to
KREKRQAKHKQAAALKS) in exon 3 is denoted by AAA. After a DrdI digest and
Southern hybridization using a 3′ flanking probe complementary to the region indicated
with the striped box, the wild-type band was 13.8 kb, while a targeted allele resulted in a
6.1-kb band. (B) Southern blot analysis revealed targeted AV3 ES cells used for morulae
aggregation here at BYU and targeted G4-56 ES cells used for microinjection at the
University of Utah, as indicated by the presence of the 6.1-kb band.
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Figure 13. Elimination of nBmp4 in zebrafish results in defective heart
development. To investigate the function of nBmp2 in development, we performed
knock-down experiments in zebrafish embryos using morpholino antisense
oligonucleotides to specifically inhibit translation from the downstream ATG in zebrafish
bmp4. (A) Amino acid sequences surrounding the site of proteolytic processing (arrow)
in zebrafish bmp4, bmp2a, and bmp2b. The predicted bmp4 bipartite NLS is shown in
bold, and the equivalent amino acids in bmp2a and bmp2b are also bold. (B) Schematic
of the nbmp4MO binding to the alternative start codon in zebrafish bmp4. (C) Injection
of the nbmp4MO into zebrafish caused obvious cardiac defects in live embryos. The
embryo on the left is a wild-type embryo while the remaining embryos represent varying
degrees of the phenotype observed. By 24 hpf, most embryos had no visible heart. By 48
hpf, a beating heart was present although it was sluggish and failed to circulate blood.
Embryos injected with the standard control MO had normal, beating hearts 24 hpf and
normal blood circulation was visible at 48 hpf.
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Figure 14. The morpholino nBmp4-MO blocks translation from the alternative,
downstream ATG but does not block translation from the conventional start codon
in vitro. To test the specificity of the nBmp4-MO, we made expression vectors for
zebrafish full-length and nuclear bmp4 and used them for in vitro transcription/translation
experiments in the presence of [35S]methionine. The expression vector for wild-type, fulllength bmp4, wtbmp4, produced the expected ~46-kDa protein (lane 1). Including the
morpholino nBmp4-MO in the reaction did not inhibit synthesis of this protein (lane 2).
The expression vector for the nuclear version of zebrafish bmp4, nbmp4, produced the
expected ~40-kDa protein (lane 3). Including nBmp4-MO in the reaction completely
inhibited synthesis of this protein (lane 4).
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zebrafish nbmp4 (Fig. 13B). Injection of the nBmp4-MO caused obvious cardiac defects
in live embryos (Fig. 13C). By 30 hpf, most embryos had no visible heart. By 48 hpf, a
beating heart was present although it was sluggish and failed to circulate blood. Embryos
injected with the standard control MO had normal, beating hearts 30 hpf and normal
blood circulation was visible at 48 hpf.

The morpholino nBmp4-MO blocks translation from the alternative, downstream
ATG but does not block translation from the conventional start codon in vitro
To test the specificity of the nBmp4-MO in vitro, we synthesized zebrafish bmp4
in the presence of [35S]methionine both with and without the morpholino present. in vitro
transcription/translation of wild-type bmp4 produced a band of the expected size at ~46
kDa; in vitro transcription/translation of the nuclear form also produced a band of the
expected size at ~40 kDa (Fig. 14). Addition of the nBmp4-MO to the full-length bmp4
in vitro transcription/translation reaction did not inhibit production of the ~46 kDa, as
expected (Fig. 14). In contrast to this, addition of the nBmp4-MO to the nuclear bmp4 in
vitro transcription/translation reaction inhibited production of the nuclear ~40 kDa (Fig.
14).

DISCUSSION
Our lab has shown for the first time that a Bmp family member is localized to the
nucleus. When we first hypothesized that a form of Bmp2 may be localized to the
nucleus, our initial step was to use the PSORT II prediction program to search the amino
acid sequence of rat Bmp2 for potential NLSs. Three were identified. To test the
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functionality of each putative NLS, we fused each to GFP. Only the bipartite NLS that
overlaps the site of proteolytic cleavage was capable of localizing GFP to the nucleus.
We later confirmed that this NLS is functional in the context of full-length Bmp2: a
wtBmp2/GFP fusion construct clearly localized to the nucleus in a portion of transfected
cells, but when the bipartite NLS was mutated, Bmp2 was no longer capable of directing
GFP to the nucleus. Since the bipartite NLS is situated at the site for proteolytic cleavage,
these results indicate that only an uncleaved version of Bmp2 could be localized to the
nucleus, a premise that was later confirmed by western blotting.
Later experiments also verified that nuclear localization of Bmp2 is not an artifact
of the GFP fusion constructs but that a form of endogenous Bmp2 is localized to the
nucleus. Immunocytochemistry using two separate antibodies clearly showed endogenous
Bmp2 in the nuclei of cultured cells. Additionally, western blots were used to show the
presence of endogenous Bmp2 in nuclear extracts from cultured cells
Before verifying the size of nBmp2 with western blots and identifying the use
of an alternative downstream start codon, we originally hypothesized that the uncleaved
version of Bmp2 resulted from regulation of proteolytic processing. Elsewhere it has
been shown that the proprotein convertase furin is responsible for processing Bmp4, and
it has long been hypothesized that Bmp2 is also cleaved by furin due to the close
homology of Bmp2 and Bmp4 and the presence of the furin recognition sequence
upstream of the cleavage site in Bmp2 (Cui et al., 1998; Mishina, 2003). Further
supporting this hypothesis, furin has been shown to modulate the activity of several of its
substrates. The pro-β-NGF protein is a neurotropin that has opposing activities depending
on whether or not it is cleaved by furin: cleaved β-NGF promotes cell survival, whereas
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uncleaved β-NGF promotes apoptosis of neurons (Lee et al., 2001). The transmembrane
receptor Notch is also cleaved by furin. When cleaved, the intracellular domain of Notch
is released and activates genes involved in development and differentiation (Mumm et al.,
2000). On the other hand, uncleaved Notch inhibits cell differentiation (Bush et al.,
2001). Since opposing activities have been reported for Bmp2, particularly with cancer,
we hypothesized that, like these proteins, Bmp2 could be regulated by furin activity.
With this information, we hypothesized that furin also modulated the activity of
Bmp2. We were able to confirm that furin can indeed cleave Bmp2 in vitro, but
regulating the activity of furin in vivo did not affect nuclear localization of Bmp2. We
also mutated the cleavage recognition sequence to prevent proteolytic processing by any
member of the proprotein convertase family. This mutation still did not affect the number
of cells demonstrating nuclear localization Bmp2.
The results of these experiments led us to hypothesize that Bmp2 nuclear
localization is achieved not through regulating Bmp2 proprotein processing but rather
through the avoidance of the secretory pathway altogether by gaining access to the
cytosol for translation. Alternative translational start sites play a significant role in
altering the localization of a number of proteins (Kochetov et al., 2005). For example, the
nuclear variant of PTHrP is translated from an alternative non-AUG start site downstream
of the conventional initiator AUG, generating a protein with a truncated signal peptide
(Nguyen et al., 2001). Similarly, the secreted growth factor bFGF can initiate at two
upstream CUG codons to produce isoforms that include N-terminal extensions containing
an NLS. These isoforms are localized to the nucleus. Spastin, a protein involved in
microtubule dynamics and membrane trafficking, has two alternative translation start
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sites. Both protein isoforms are targeted to the nucleus, but one of the isoforms also
contains two nuclear export signals that efficiently drive export into the cytoplasm
(Claudiani et al., 2005). Wnt13B and Wnt13C also have alternative translation start
codons, the use of which determines whether they are localized to the nucleus or to the
mitochondria (Struewing et al., 2006).
Our data indicate that, like these other growth factors, the nuclear version of
Bmp2 results from the use of an alternative translational start site. We mutated the
conventional start codon to force utilization of any downstream start codon within the
Bmp2/GFP fusion construct. This mutation dramatically increased the amount of Bmp2
nuclear localization. Examination of the region downstream of the signal peptide led to
the identification of an in-frame ATG that, when mutated, significantly decreaseds the
frequency of nuclear localization. The protein produced by initiating translation at this
site would lack the N-terminal signal peptide and would therefore bypass the rER and
secretory pathway where the proteolytic cleavage would otherwise occur. Following
cytoplasmic translation, the intact bipartite NLS could then direct translocation to the
nucleus. The fact that some nuclear localization (10%) was still observed when this
downstream ATG was mutated suggests utilization of one or more additional alternative
start codons that also truncate the N-terminal signal peptide.
Further supporting our alternative start codon data are the results of our western
blots. A band that corresponds to the predicted size of nBmp2 (calculated from the
alternative downstream ATG to the end of the classical mature region at 38.6 kDa) was
present in these blots. To confirm that this is in fact nBmp2, nuclear extracts from cells
transfected with an HA-tagged version of Bmp2 were used for western blots, and again
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the ~38.6 kDa band was present. This verification of the size of nBmp2 as ~38.6 kDa
supports the hypothesis that nBmp2 is an uncleaved version that results from translation
at the alternative start codon.
Having verified the existence of nBmp2 and identified the manner by which it
escapes the secretory pathway, we were next interested in uncovering the function of
nBmp2. We determined to generate mice that lack nBmp2 but still produce secreted
Bmp2. To do this, we had two options: we could either mutate the alternative start codon
or the NLS. Since mutating the alternative start codon decreased the amount of nuclear
localization by half while mutating the NLS eliminated nuclear localization, we decided
to mutate the NLS. Choosing how to mutate the NLS was complicated by the fact that the
RKR-K portion of the NLS is within the mature region of Bmp2, and the KR portion of
the NLS overlaps the recognition sequence for furin. Changing these amino acids had the
potential to alter the function of the secreted Bmp2 or to prevent processing of Bmp2, in
essence creating a Bmp2 knockout mouse.
Targeted mutagenesis experiments determined that mutating the RKR portion of
the NLS would prevent nuclear localization. We performed additional experiments and
verified that mutating the RKR portion of the NLS does not decrease secretion of Bmp2.
Data reported by others suggested that this mutation would also have minimal affect on
the function of the secreted Bmp2: Hillger et al. showed that Bmp2 species truncated Nterminally of either the R, K or R still had the capability to induce ectopic bone formation
(Hillger et al., 2005). When the equivalent sequence in Bmp4 was deleted or substituted
with three Ala residues and subjected to a battery of tests for receptor binding, antagonist
binding, and target gene responsiveness, they showed that the mature Bmp4 homodimer
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bearing the mutation was functionally indistinguishable from the wild-type Bmp4
(Ohkawara et al., 2002). However, animal cap conjugation experiments with Xenopus
embryos demonstrated that these mutations reduced the ability of Bmp4 to bind heparin
sulfate in the extracellular matrix with the result of increased diffusion range (Ohkawara
et al., 2002). Because Bmp2 and Bmp4 are so highly related, these results strongly
suggest that Bmp2 bearing the same mutations would also function normally, perhaps
with a slightly increased diffusion range.
A similar increase in the diffusion range of Bmp2 growth factor produced in our
mice could result in a phenotype that is not related to the loss of nBmp2. When
evaluating the phenotype displayed in the nBmp2 null mouse, we will have to be aware
of the possibility for an increased diffusion range of the secreted Bmp2 growth factor.
Fortunately since the zebrafish morpholino experiments only block translation of the
nuclear variant without producing any change in the amino acid sequence, the zebrafish
results can be used to aid evaluation of the mouse phenotype. Any phenotype that appears
in both zebrafish and in the nBmp2 null mouse can confidently be attributed to loss of
nBmp2 rather than to a gain of growth factor diffusion range. If questions about the
mouse phenotype arise that cannot be resolved by comparison to the zebrafish phenotype,
nBmp2 transgene rescue experiments in the mouse can be performed to see if the mouse
nBmp2-ko phenotype can be rescued by addition of nuclear-only Bmp2 in a tissue
specific fashion.
The nBmp2-ko targeting vector was constructed using recombineering, a phagebased E. coli homologous recombination system pioneered by Dr. Neal G. Copeland of
the National Cancer Institute. The targeting vector has a mutated and, therefore non-
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functional, NLS, a Neo selection cassette, and a TK gene used for selection of
homologous recombinants. Chimeric mice carrying the defective Bmp2 allele have been
generated, and the process of breeding to homozygosity is underway.
While constructing the nBmp2-ko targeting vector and generating nBmp2-null
mice, we investigated the function of nBmp2 by performing both a microarray and
knockdown experiments in zebrafish. For the microarray experiments, we overexpressed
nBmp2 in cell culture and compared the gene expression profile to that of cells
transfected with the empty expression vector. The genes that had significant differences
in expression largely clustered into genes involved with nervous system development and
function, lipid metabolism, immune system functioning, and cancer. To collect more
information from the microarray experiments, on-going work in the Bridgewater lab is
focused on optimizing the real-time PCR parameters such as cDNA synthesis, primer
design, and template concentration.
The zebrafish work has proved to be more promising in identifying a role of
nBmp2. We chose to use morpholinos to block translation of nBmp2. When base paired
at the translational start site, morpholinos prevent initiation of translation. When annealed
to mRNA more than 30 bases downstream of the start site, however, the morpholinos are
displaced by the ribosome and have no effect on translation (Gene Tools, LLC Targeting
Guidelines, http://www.gene-tools.com/node/18). Therefore, morpholinos should work
perfectly to block translation of nBmp2 and not secreted Bmp2, but to our knowledge this
technology has never been used to block translation of a downstream alternative start
codon. Our in vitro transcription/translation experiments verified that the nBmp4-MO did
in fact block translation from the alternate, downstream start codon but did not affect
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translation from the conventional start codon as expected. Also, as a control we injected
zebrafish with a splice-blocking morpholino known to inhibit translation of bmp4. These
fish exhibited a different phenotype than our nBmp4-MO injected fish.
In zebrafish, three different BMP proteins are all equally homologous with rat
Bmp2: zebrafish bmp2a, bmp2b, and bmp4 proteins all have 60-62% sequence identity
with rat Bmp2. bmp2a and bmp2b, however, may not contain functional bipartite NLSs.
The characteristic pattern of bipartite NLS is two basic residues, nine or ten spacer
residues, and another basic region consisting of four basic residues out of five (Cyert,
2001). Zebrafish bmp4 contains a characteristic bipartite NLS overlapping the site of
proteolytic cleavage. bmp2a and bmp2b, on the other hand, are both missing one of the
first two basic residues, unless the downstream KR residues just before the cleavage site
serve the purpose, in which case the spacer is reduced to only six or seven residues. We
therefore chose to knockdown zebrafish bmp4. Since bmp4 is as homologous to rat Bmp2
as bmp2a and bmp2b, a phenotype from knocking-down zebrafish nbmp4 would suggest
the importance of nBmp2 for all vertebrates, including mammals.
Zebrafish embryos injected with a morpholino designed to block translation only
of nbmp4, leaving secreted bmp4 intact, did indeed develop a significant phenotype: the
majority of embryos developed severe heart defects. Interestingly, zebrafish embryos are
not completely dependent on a functional cardiovascular system. Even without effective
blood circulation, they receive enough oxygen by passive diffusion to survive for several
days (Stainier, 2001). Additionally, their translucent skin facilitates visualizing the
developing heart. Work is currently in progress to verify in vivo what we observed in
vitro: that secreted bmp4 is present in normal amounts and that nbmp4 is, in fact, lacking.
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This work includes western blot analysis on nuclear extracts as a means to visualize
nbmp4 in wild-type fish but not in morphant fish. Also, rescue experiments are planned;
these experiments will entail injecting nBmp4-MO and an excess of mRNA for nbmp4
into zebrafish embryos to determine if adding nbmp4 back into the morphant fish can
rescue the phenotype. Since a phenotype for overexpression of nbmp4 is possible, the
appropriate ratio of nBmp4-MO and nbmp4 mRNA to inject will need to be determined.
Several of the genes the microarray data indicated were regulated by nBmp2 are
important in heart development. Neuregulin (Nrg1) morphant fish, for example,
displayed inhibited conductive tissue development that resulted in slowed conduction
throughout the heart (Milan et al., 2006). Blood vessel/epicardial substance (Bves/Pop1)
is highly enriched in the developing heart and is the earliest known marker of cardiac
vascular smooth muscle (Andree et al., 2000; Reese and Bader, 1999; Reese et al., 1999).
Evidence suggests that Bves plays a role in cell adhesion and migration in the developing
heart (Wada et al., 2001). Erythropoietin also had a significant change in expression in
response to nBmp2. It plays a significant role in heart morphogenesis and differentiation
of cardiac cells from embryonic stem cells (Sachinidis et al., 2002; Wu et al., 1999).
Matrix metalloproteinase 2 (Mmp2) is another gene of interest: inhibition of Mmp2 in
developing chick embryos produced severe heart tube defects (Linask et al., 2005). To
better understand the heart defects in zebrafish, expression of these genes and others will
be studied in future work involving in situ hybridization and real-time PCR on wild-type
and morphant zebrafish.
In conclusion, this dissertation represents a body of work that points to a new
paradigm for Bmp2 functioning. We have shown that a nuclear variant of Bmp2 does in
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fact exist and that it is produced by translation from an alternative downstream start
codon. We have also demonstrated that nBmp2 is critical for developing vertebrates;
zebrafish lacking this protein have severe heart defects. To illuminate the role of nBmp2
in mammalian development, we have also designed a mouse model that will lack nBmp2
but retain the function of secreted Bmp2. Chimeric mice harboring this mutation have
been generated, and, once breeding to homozygosity is complete, functional distinction
between the nuclear and secreted forms of this protein will be possible. The original work
detailed in this dissertation has opened new avenues of research that will make significant
contributions toward understanding the full role BMP proteins play in development.
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BOOK II

COORDINATE REGULATION OF COL11A2 AND COL27A1
BY THE TRANSCRIPTION FACTOR LC-MAF
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INTRODUCTION
Maf proteins
Maf family proteins belong to the basic leucine zipper (bZIP) superfamily of
transcription factors; they contain a leucine zipper dimerization interface adjacent to a
basic DNA binding region (Motohashi et al., 1997). However, the basic regions of the
Maf family of proteins contain non-conservative amino acid substitutions at positions that
are highly conserved in other bZIP proteins. Maf proteins also contain an additional
DNA-binding region on the N-terminal side of the bZIP domain that is highly conserved
and required for specific DNA recognition (Kerppola and Curran, 1994). These
differences result in a different tertiary structure and DNA contact interface than the
canonical bZIP proteins (Dlakic et al., 2001). Until recently, Maf proteins have only been
known to recognize longer DNA sequence elements (13-14 bp) that extend past the
typical bZIP recognition element (Dlakic et al., 2001; Kataoka et al., 1994; Kerppola and
Curran, 1994).
Individual Maf proteins can be widely expressed in diverse cell types and yet are
involved in the expression of a variety of tissue-specific gene products both during and
after development (de Crombrugghe et al., 2000; Ho et al., 1996; Huang et al., 2002;
Kurschner and Morgan, 1995; Reza and Yasuda, 2004). This characteristic appears to be
due, in part, to the ability of bZIP proteins to form heterodimers with a wide variety of
other transcriptional regulatory proteins. Due to the nature of dimer formation among
bZIP proteins, in which both proteins independently recognize one half of the DNA
recognition sequence, Maf recognition elements frequently differ from each other
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(Kerppola and Curran, 1994). It has been suggested that Maf proteins acquire their
ability to regulate expression of such a diversity of genes through interacting with
different transcriptional regulatory proteins in the developing tissues and thereby
recognizing a variety of target-specific DNA elements (Dlakic et al., 2001; Hale et al.,
2000; Ho et al., 1998; Kim et al., 1999; Motohashi et al., 1997).
Maf proteins may also play a role in carcinogenesis. c-maf is a cellular homologue
of the avian viral oncogene v-Maf (MacLean et al., 2003). v-Maf was identified as the
transforming gene of the avian retrovirus, musculoaponeurotic fibrosarcoma, which,
when inoculated into newborn chickens, induces tumors (Kawai et al., 1992). v-Maf
introduced into chicken embryo fibroblasts leads to cellular transformation (Kawai et al.,
1992). c-Maf, without any structural modification in its protein-coding region, was shown
to transform cells as efficiently as v-Maf when transduced by a retroviral vector into
chicken embryo fibroblasts. Amino acid sequence analysis revealed few differences
between v-Maf and chicken c-Maf. Further comparison revealed the chicken c-Maf to be
highly conserved at the primary amino acid level with a number of mammals (Kataoka et
al., 1993). Subsequent investigations revealed c-Maf as a human oncoprotein that was
overexpressed in 25% of multiple myelomas that were tested (Chesi et al., 1998).
Interestingly, both v-Maf and c-Maf are also shown to activate p53 expression by binding
to a Maf recognition sequence in the p53 promoter, leading to p53-dependent cell death
when overexpression of v-Maf exists in primary cells (Hale et al., 2000). Functional
differences between c-Maf and a long form of c-Maf, Lc-Maf, are still unknown, but it
has been suggested that they posses redundant functions since they share similar Northern
and in situ hybridization patterns. It has also been suggested that v-Maf may be derived
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from Lc-Maf rather than c-Maf since they both have a similar extra 10 amino acids
(Huang et al., 2002).
A different form of c-Maf that includes a different 3′UTR region and an
additional 10 amino acids at the carboxyl terminus, Lc-Maf, was identified in a yeast
two-hybrid screen by its specific interaction with SOX9, a known transcriptional
activator of a number of cartilage-specific genes, including those for the type II, IX, XI,
and XXVII collagens (Bridgewater et al., 1998; Bridgewater et al., 2003; Huang et al.,
2002; Jenkins et al., 2005; Zhang et al., 2003). Lc-Maf was shown to synergize with
SOX9 to increase the expression of the cartilage-specific Col2a1 gene in 10T1/2 cells
and MC615 chondrocytes by binding within a Col2a1 enhancer element to the short, 7-bp
recognition element GGCTCTG (Huang et al., 2002). Lc-Maf appears to be a splice
variant of c-Maf as it has a different 3′UTR region and an additional 10 amino acids at
the carboxyl terminus (Huang et al., 2002). Using a probe from the 3′UTR of Lc-Maf,
northern hybridizations revealed RNA expression in various mouse tissues, including
cartilage (Huang et al., 2002). It has been demonstrated that the presence of Lc-Maf and
c-Maf in cartilage plays a vital role for correct skeletal development: mice lacking these
proteins exhibited decreased fetal bone length and had improper hypertrophic
chondrocyte differentiation (MacLean et al., 2003).
Cartilage
Cartilage is an important tissue that serves a vital role as the template for many
bones in the developing skeleton. During the process of endochondral ossification, long
bones of the body develop from a cartilage intermediate that is progressively replaced by
bone. During the first phase, the mesenchyme cells differentiate into chondrocytes.
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Starting at the center of the cartilaginous template and progressing towards the epiphyses,
these cells mature from resting to proliferating and on to hypertrophic chondrocytes, at
which point mineralization begins (Fig. 1). At each stage of chondrocyte differentiation,
the expression of extracellular matrix proteins are temporally and spatially coordinated
due to a tight regulation via transcription factors, signaling molecules, hormones and
local growth factors (Huang et al., 2002; Tchetina et al., 2003). Precise coordination of
the expression of extracellular matrix proteins, such as the cartilage-specific collagens, is
essential for correct skeletal development.
We investigated the role Lc-Maf might play in regulating enhancers of other
cartilage specific collagen genes during development of the long bones, namely the B/C,
D/E, and F/G enhancer elements of Col11a2 and the 27D/E and 27F/G enhancer elements
of Col27a1 (Fig. 2A and B). Like Col2a1, these enhancer elements are also responsive to
SOX9 (Bridgewater et al., 1998; Bridgewater et al., 2003; Jenkins et al., 2005; Liu et al.,
2000; Pace et al., 2003). Our findings indicate that the transcription factor Lc-Maf can
both positively and negatively regulate enhancer elements from these two different
cartilage-specific collagen genes and may play an important role in the coordinated
regulation of Col11a2 and Col27a1 during embryonic development of fetal limbs.
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Figure 1. Model of endochondral ossification. During the process of endochondral
ossification, long bones of the body develop from a cartilage intermediate that is
progressively replaced by bone. The process of cellular maturation starts at the center of
the cartilaginous template and progresses towards the epiphyses; the most mature cells
are at the center of the diaphysis while the most immature are located at either epiphysis.
This image depicts mineralized bone at the center of the diaphysis. These cells have
already matured from resting, to proliferating and on to hypertrophic chondrocytes before
ossification began, while the cells on either side of this center of ossification are still
maturing.
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Figure 2. Schematic diagrams of the Col11a2 and COL27A1 cartilage-specific
enhancer regions. (A) A schematic diagram of the 5′ region of Col11a2 showing the
B/C and D/E enhancer elements in the upstream promoter region and the F/G enhancer in
the first intron, represented as boxes. (B) A schematic diagram of the 5′ region of
COL27A1 showing the 27D/E and the 27F/G enhancer elements in the first intron,
represented as boxes. Expanded views of each enhancer element show approximate
locations of the two Sox9-binding sequences (open boxes).
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METHODS
Plasmids
Each of the experimental constructs used in transient transfections contained four
tandem copies of an enhancer element, cloned upstream of the 95-bp Col2a1 minimal
promoter and a luciferase reporter gene. Enhancer elements tested in plasmids
4×(B/Cm1)p95Luc, 4×(B/Cm2)p95Luc, 4×(D/Em)p95Luc, 4×(27D/E)p95Luc, and
4×(27F/Gm)p95Luc were synthesized as complementary oligonucleotides purchased
from Invitrogen (Carlsbad, CA). Oligonucleotides were purified by denaturing
polyacrylamide gel electrophoresis before annealing. The plasmid p89Col2a1Bs was used
to multimerize the enhancer elements before transferring them, along with the Col2a1
minimal promoter, into the luciferase reporter vector pLuc4 as previously described
(Bridgewater et al., 1998; Lefebvre et al., 1996). All other luciferase reporter plasmids
were made previously (Bridgewater et al., 1998; Bridgewater et al., 2003; Jenkins et al.,
2005). The SOX9 expression plasmid, SOX9-pcDNA-5′-UT, and p89Col2a1Bs were
kind gifts from Dr. Veronique Lefebvre of the Cleveland Clinic in Cleveland, Ohio. The
Lc-Maf expression vector was a kind gift from Dr. Wendong Huang of the Baylor
College of Medicine in Houston, Texas.

Cell Types and Culture
Rat chondrosarcoma (RCS) cells and BALB/3T3 fibroblasts were maintained for
use in transient transfection assays. Both cell lines were cultured at 37°C under 5% CO2
in Dulbecco’s modified Eagle’s medium, supplemented with penicillin (50 units/ml),
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streptomycin (50 µg/ml), L-glutamine (2mM) and 10% bovine growth serum. Every 3-4
days the cells were passaged using a 0.25% trypsin-1mM EDTA solution.

Transient Transfections
The transient transfections were performed in both RCS and BALB/3T3 cell lines.
The enhancer/reporter gene constructs were cotransfected with Lc-Maf and SOX9
expression plasmids (pcDNA3.1-Lc-Maf and SOX9-pcDNA-5′-UT) to determine the
effect of Lc-Maf on transcriptional activity, both alone and in conjunction with SOX9, a
known transcriptional activator for the Col2a1, Col11a2, and COL27A1 enhancer
elements. All transfections were performed in triplicate and repeated at least three times.
The plasmid pSV-β-galactosidase (Promega) was included in every reaction as an
internal control for transfection efficiency.
Transfections were performed using LipofectAMINE PLUS reagent (Invitrogen)
according to the manufacturer’s protocol. A total of 2 µg of DNA was used to transfect
each 10-cm2 dish. For RCS cells, each reaction included 1.0 µg of the luciferase reporter
plasmid, 0.5 µg of pSV-β-galactosidase as an internal control for transfection efficiency
and 0.5 µg of either pcDNA3.1-Lc-Maf or the empty pcDNA3.1 vector. For BALB/3T3
fibroblasts, each reaction included 1.0 µg of the luciferase reporter plasmid, 0.4 µg of
pSV-β-galactosidase as an internal control for transfection efficiency and 0.3 µgcombinations of either pcDNA3.1-Lc-Maf, SOX9-pcDNA-5′-UT, or the empty
pcDNA3.1 vector for a total of 0.6 µg. β -galactosidase levels were measured using the
Galacto-Light/Plus system (Tropix, Bedford, MA) following the manufacturer’s protocol.
Luciferase levels were measured using the Luciferase Assay Reagent (Promega.
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Madison, WI) following the manufacturer’s protocol. Transfection data is reported as
Relative Luciferase Units (luciferase units per β-galactosidase unit) ± standard error
(s.e.m.) and each graph represents at least three independent transfections, each
performed in triplicate.

In Vitro Transcription/Translation
Lc-Maf protein was synthesized using the Single Tube Protein System 3, T7 kit
(Novagen, San Diego, CA) according to manufacturer’s instruction using the Lc-Maf
expression plasmid, pcDNA3.1-Lc-Maf. To verify that both transcription and translation
occurred as expected, [35S]methionine-labeled Lc-Maf was visualized on SDS-PAGE.

Electrophoretic Mobility Shift Assay (EMSA)
Wild-type and mutant COL27A1 27F/G probes were prepared by annealing
complementary oligonucleotides synthesized by Invitrogen. The probes were labeled by
end-filling with α-[32P]dGTP using the Klenow fragment and purified using Amersham
Biosciences NICK columns according to manufacturer’s protocol (Amersham
Biosciences, Piscataway, NJ). Labeled probes were adjusted with unlabeled probe to
achieve equivalent specific activities. Lc-Maf protein was pre-incubated for 15 minutes in
20 µl buffer containing 20 mM HEPES, 100mM KCl, 10mM MgCl2, 5% glycerol, 1 mM
EDTA, 5 mM DTT, 0.1% NP-40, 0.5 mg ml-1 BSA, and 1 µg poly(dGdC)·poly(dGdC)
(Amersham Biosciences, Piscataway, NJ). Addition of antibody, if included, took place at
this incubation step. Since Lc-Maf differs from c-Maf by only an additional 10 amino
acids at the carboxyl terminus, an antibody directed towards the amino terminus of c-Maf
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was used (Santa Cruz Biotechnology, Santa Cruz, CA). Radiolabeled probe was added to
the binding reaction and incubated at room temperature for an additional 15 minutes.
The samples were then fractionated by electrophoresis through a non-denaturing 4%
polyacrylamide gel in 0.5× TBE at 140 V and visualized by autoradiography.

Synthesis and labeling of in situ hybridization probes
In situ hybridization probes for the mouse Col10a1, Col11a2, Col27a1,and LcMaf genes were kind gifts from the following individuals: Col10a1 from B. de
Crumbrugghe, Col11a2 from Y. Yamada, Col27a1 from J. Pace and Lc-Maf from W.
Huang. Additionally, a probe directed against the third exon of Col27a1 was synthesized
via PCR from mouse genomic DNA. The primer sequences we used were 5′CATCCGCAGCAGGAAACAC and 5′-CAGCTGCGTTCAGAGACATC. The probe’s
specificity for Col27a1 was verified by using the Basic Local Alignment Search Tool
(BLAST). Single-strand RNA antisense probes were labeled with digoxigenin-11-UTP
using the DIG RNA labeling kit (Roche, Indianapolis, IN) according to manufacturer’s
protocol.

In situ hybridizations and Immunohistochemistry
Mouse embryos were collected at half-day intervals from embryonic day 15-17
(E15-E17). Forelimbs were removed, fixed overnight at 4°C in 4%
paraformaldehyde/phosphate-buffered saline (PFA/PBS), embedded in paraffin wax, and
sectioned (6-8 µm) before placing onto Superfrost/Plus microscope slides (Fisher) to
make a series of slides with adjacent tissue sections.
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In situ hybridization was performed following the protocol of Murtaugh
(Murtaugh et al., 1999) with the following modifications: after incubation with 1 µg/mL
proteinase K (Fisher) for 30 minutes at 37°C and washing with PBT (phosphate-buffered
saline plus 0.1% Tween-20), sections were postfixed in 4% PFA/PBS and incubated 4
hours in a humid chamber with prehybridization buffer. Hybridization to digoxigenin-11UTP-labeled probes for the Col10a1, Col11a2, Col27a1, and Lc-Maf genes was carried
out in a humid chamber overnight in the same hybridization mixture. Following
hybridization, sections were treated with RNAse A (Fisher) in TNE (10 mM Tris pH 7.5,
500mM NaCl, 1 mM EDTA) and washed in SSC (15 mM sodium citrate, 150 mM NaCl,
pH 7.0). The sections were blocked using 10% serum/MABT (100 mM Maleic Acid, 150
mM NaCl, 0.1% Tween-20, pH 7.5) before visualizing the probes by staining with antiDIG-alkaline phosphatase-conjugated antibody (Roche, Indianapolis, IN) and treating the
slides with BM Purple (Fisher).
Immunohistochemistry was performed as described previously (Barrow et al.,
2003) using primary antibody directed against mature type XXVII collagen. This
antibody was designed, generated, and generously provided by J. Pace.

RESULTS
Lc-Maf interacts specifically with the Col11a2 chondrocyte-specific B/C enhancer
element to repress activity
The Col11a2 wild-type luciferase reporter construct 4×(B/C)p95Luc was
cotransfected with the Lc-Maf expression vector, pcDNA3.1-Lc-Maf, into both RCS and
BALB/3T3 cells to determine whether Lc-Maf exerts any regulatory action on this

92

enhancer element, which contained a putative Lc-Maf binding sequence (Fig. 3E). The
reporter construct was active in RCS cells but inactive in fibroblasts, demonstrating the
expected cell-type specificity of the chondrocytic enhancer’s activity (data not shown).
The SOX9 expression plasmid activated the enhancer in fibroblasts as previously
demonstrated (Bridgewater et al., 1998; Bridgewater et al., 2003).
When pcDNA3.1-Lc-Maf was cotransfected with 4×(B/C)p95Luc in RCS cells, a
significant decrease in luciferase production was measured to 50% of the original B/C
value (p≤ 0.0001) (Fig. 3A). Similar results were obtained when the reporter construct
was cotransfected with pcDNA3.1-Lc-Maf and SOX9-pcDNA-5′-UT in BALB/3T3
fibroblasts: SOX9-induced luciferase production from 4×(B/C)p95Luc was significantly
reduced by Lc-Maf to 79% (p≤ 0.0004) (data not shown).
Mutations were introduced into the Col11a2 B/C enhancer element at the putative
Lc-Maf binding sites to test for direct binding of Lc-Maf to these enhancers. Two
separate sequences existed within the B/C enhancer element with similarity to the
previously reported GGCTCTG binding sequences, so mutant enhancers B/Cm1 and
B/Cm2 were designed to target these two putative binding sites (Fig. 3E). When the
Col11a2 mutant reporter construct 4×(B/Cm1)p95Luc was cotransfected with
pcDNA3.1-Lc-Maf, the B/Cm1 mutant enhancer was not responsive to Lc-Maf (Fig. 3B).
However, B/Cm2 responded similarly to Lc-Maf overexpression as the wild-type B/C
enhancer (Fig. 3C). This suggests that Lc-Maf interacts specifically with the B/C
enhancer element at the region mutated in B/Cm1. Interestingly, both mutant B/C
enhancer elements were less active than the B/Cwt enhancer element, suggesting that the
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Figure 3. Lc-Maf interacts specifically with the Col11a2 B/C enhancer element to
inhibit enhancer activity. (A-D) RCS cells were transiently transfected with Col11a2
B/C wild-type or mutant enhancer/reporter plasmids plus pcDNA3.1Lc-Maf (Lc-Maf) or
the empty pcDNA3.1 vector (E.V.) as indicated. Enhancer activities that are significantly
different from the corresponding wild-type enhancer activities are indicated with an
asterisk (p ≤ 0.009). (E) The wild-type Col11a2 B/C sequence is shown with the Sox9
binding regions in bold and the putative Lc-Maf binding regions in bold and underlined.
The nucleotide substitutions for the mutant enhancers are indicated below the wild-type
sequences.
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mutated region also binds a positive regulatory factor, perhaps one that competes with
Lc-Maf for binding (Fig. 3D).

Lc-Maf interacts specifically with the Col11a2 chondrocyte-specific D/E enhancer
element to repress activity
The Col11a2 wild-type luciferase reporter constructs 4×(D/E)p95Luc was
cotransfected with the Lc-Maf expression vector, pcDNA3.1-Lc-Maf, into both RCS and
BALB/3T3 cells to determine whether Lc-Maf exerts any regulatory action on this
enhancer elements, which contained a putative Lc-Maf binding sequence (Fig. 4D). The
reporter construct was active in RCS cells but inactive in fibroblasts, demonstrating the
expected cell-type specificity of the chondrocytic enhancer’s activity (data not shown).
The SOX9 expression plasmid activated all the enhancer in fibroblasts as previously
demonstrated (Bridgewater et al., 1998; Bridgewater et al., 2003).
When pcDNA3.1-Lc-Maf was cotransfected with 4×(D/E)p95Luc in RCS cells, a
significant decrease in luciferase production was measured to 65% of the original D/E
value (p≤ 0.0002) (Fig. 4A). Similar results were obtained when this reporter construct
was cotransfected with pcDNA3.1-Lc-Maf and SOX9-pcDNA-5′-UT in BALB/3T3
fibroblasts: SOX9-induced luciferase production from 4×(D/E)p95Luc was significantly
reduced by Lc-Maf to 64% (p≤ 0.0004).
For the Col11a2 D/E enhancer element, the mutant enhancer D/Em targeted the
putative Lc-Maf binding site (Fig. 4D). When the Col11a2 mutant reporter construct
4×(D/Em)p95Luc was cotransfected with pcDNA3.1-Lc-Maf, the D/Em mutant enhancer
was no longer responsive to Lc-Maf, suggesting that the specific interaction between Lc-
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Figure 4. Lc-Maf interacts specifically with the Col11a2 D/E enhancer element to
inhibit enhancer activity. (A-C) RCS cells were transiently transfected with wild-type
or mutant enhancer/reporter plasmids plus pcDNA3.1Lc-Maf (Lc-Maf) or the empty
pcDNA3.1 vector (E.V.) as indicated. Enhancer activities that are significantly different
from the corresponding wild-type enhancer activities are indicated with an asterisk (p ≤
0.018). (D) The wild-type Col11a2 D/E sequence is shown with the Sox9 binding regions
in bold and the putative Lc-Maf binding regions in bold and underlined. The nucleotide
substitutions for the mutant enhancers are indicated below the wild-type sequences.
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Maf and the D/E enhancer element occurs within the region mutated in D/Em (Fig. 4B).
Comparison of the activities of the D/Ewt and the D/Em enhancers showed that D/Em
was more active, consistent with the loss of a negative regulatory element (Fig. 4C).

Lc-Maf does not regulate the activity of the Col11a2 F/G enhancer element
As with the other Col11a2 enhancer elements, the Col11a2 wild-type luciferase
reporter construct 4×(F/G)p95Luc was cotransfected with pcDNA3.1-Lc-Maf into both
RCS and BALB/3T3 cells to determine whether Lc-Maf exerts any regulatory action on
this enhancer element, which contained a putative Lc-Maf binding sequence (Fig. 5B).
No significant difference in luciferase production was detected, suggesting that Lc-Maf
does not regulate this enhancer (p= 0.38) (Fig. 5A).
Similar results were obtained when this reporter construct was cotransfected with
pcDNA3.1-Lc-Maf and SOX9-pcDNA-5′-UT in BALB/3T3 fibroblasts: Lc-Maf did not
activate or inhibit 4×(F/G)p95Luc when compared to the SOX9-induced luciferase
production (p= 0.41) (data not shown).

Lc-Maf does not regulate the COL27A1 chondrocyte-specific 27D/E enhancer
element
The COL27A1 wild-type luciferase reporter construct 4×(27D/E)p95Luc was also
cotransfected with the Lc-Maf expression vector, pcDNA3.1-Lc-Maf, into both RCS and
BALB/3T3 cells to determine whether Lc-Maf exerts any regulatory action on this
enhancer element, which contained a putative Lc-Maf binding sequence (Fig. 6B). This
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Figure 5. Lc-Maf does not modulate the activity of the Col11a2 F/G enhancer
element. (A) RCS cells were transiently transfected with wild-type Col11a2 F/G
enhancer/reporter plasmid plus pcDNA3.1Lc-Maf (Lc-Maf) or the empty pcDNA3.1
vector (E.V.) as indicated. (B) The wild-type Col11a2 F/G sequence is shown with the
Sox9 binding regions in bold and the putative Lc-Maf binding regions in bold and
underlined.
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Figure 6. Lc-Maf does not modulate the activity of the COL27A1 27D/E enhancer
element. (A) RCS cells were transiently transfected with wild-type COL27A1 D/E
enhancer/reporter plasmids plus pcDNA3.1-Lc-Maf (Lc-Maf) or the empty pcDNA3.1
vector (E.V.) as indicated. (B) The wild-type COL27A1 27D/E sequence is shown with
the Sox9 binding regions in bold and the putative Lc-Maf binding region in bold and
underlined.
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reporter construct was active in RCS cells but inactive in fibroblasts, demonstrating the
expected cell-type specificity of the chondrocytic enhancer’s activity. The SOX9
expression plasmid activated the enhancer in fibroblasts as previously demonstrated
(Jenkins et al., 2005). However, when pcDNA3.1-Lc-Maf was cotransfected with
4×(27D/E)p95Luc into RCS cells no regulatory action was detected, despite the existence
of a sequence similar to the previously reported Lc-Maf binding sequence (Fig. 6A).

Lc-Maf interacts specifically to activate the COL27A1 chondrocyte-specific 27F/G
enhancer element
The COL27A1 wild-type luciferase reporter construct 4×(27F/G)p95Luc was
cotransfected with the Lc-Maf expression vector, pcDNA3.1-Lc-Maf, into both RCS and
BALB/3T3 cells to determine whether Lc-Maf exerts any regulatory action on this
enhancer element. The reporter construct was active in RCS cells but inactive in
fibroblasts, demonstrating the expected cell-type specificity of the chondrocytic
enhancer’s activity. The SOX9 expression plasmid activated the enhancer element in
fibroblasts as previously demonstrated (Jenkins et al., 2005).
Cotransfection of the COL27A1 reporter plasmid 4×(27F/G)p95Luc with
pcDNA3.1-Lc-Maf in RCS cells led to a 4.5-fold increase in reporter gene expression
compared to the luciferase level from 4×(27F/G)p95Luc alone (p= 0.0002) (Fig. 7A). It
was previously reported that cotransfection of Lc-Maf and SOX9, a known activator of
the cartilage-specific collagen enhancer elements, led to a synergistic activation of the
Col2a1 48-bp enhancer element (Huang et al., 2002). Such synergistic activation of the
COL27A1 27F/G enhancer element was also evident in BALB/3T3 fibroblasts: forced
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Figure 7. Lc-Maf activates the COL27A1 27F/G enhancer element by binding to a
novel Maf binding sequence. (A-C) RCS cells were transiently transfected with wildtype or mutant enhancer/reporter plasmids plus pcDNA3.1-Lc-Maf (Lc-Maf) or the
empty pcDNA3.1 vector (E.V.) as indicated. Enhancer activities that are significantly
different from the corresponding wild-type enhancer activities are indicated with an
asterisk (p ≤ 0.0004). (D) Electrophoretic mobility shift assays were performed with the
COL27A1 27F/Gwt and 27F/Gm enhancer elements as DNA probes with in vitro
transcribed and translated Lc-Maf protein and c-Maf antibody as indicated. The arrow
indicates the DNA-protein complex formed between the 27F/Gwt probe and in vitro
made Lc-Maf. Addition of the c-Maf antibody in lane two interfered with formation of
this complex. Lane 3 shows that the same 2-basepair mutation that prevented Lc-Maf
from activating the 27F/Gwt enhancer in transient transfections also reduces Lc-Maf
binding to the enhancer in EMSA. (E) The wild-type COL27A1 27F/G sequence is shown
with the Sox9 binding regions in bold and the best-available Lc-Maf binding region in
bold and underlined. The nucleotide substitutions for the mutant enhancer are indicated
below the wild-type sequence.

101

expression of either SOX9 or Lc-Maf resulted in a 12.5-fold increase or a 6.5-fold
increase in enhancer activity, respectively, while coexpression of both SOX9 and Lc-Maf
resulted in a more-than-additive, 26-fold, activation of 27F/G enhancer activity (data not
shown).
Neither an Lc-Maf consensus binding sequence nor any complete Maf-family
consensus binding sequence could be identified within the COL27A1 27F/G enhancer
element, but there appeared to be a half sequence (AAAGACTTGA) at the 5′ end of the
probe. A 2-basepair mutation was introduced in this area (AAAGAATTAA) (Fig. 7E).
The activity of the mutant enhancer 27F/Gm, in which the 2-basepair mutation was
introduced, was tested in transient transfections in both RCS and BALB/3T3 fibroblasts.
When the COL27A1 27F/Gm mutant reporter construct 4×(27F/Gm)p95Luc was
cotransfected with pcDNA3.1-Lc-Maf, the 27F/Gm mutant enhancer was no longer
activated by Lc-Maf, suggesting that the mutation in 27F/Gm disrupts the interaction
between the enhancer element and Lc-Maf (Fig. 7B). Comparison of the activities of the
27F/Gwt and the 27F/Gm enhancers showed that the mutant enhancer was only 20% as
active as the wild-type, consistent with the loss of a positive regulatory element (Fig. 7C).

The 2-basepair mutation in the mutant enhancer 27F/Gm diminishes the ability of
Lc-Maf to bind to the COL27A1 27F/G enhancer element.
Since the transfection experiments showed that Lc-Maf could only activate the
wild-type COL27A1 27F/G enhancer and not the mutant enhancer 27F/Gm, EMSA
experiments were performed with both the wild-type and mutant enhancers to verify that
this activation was a result of Lc-Maf binding to the DNA. EMSAs showed that in vitro
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transcribed and translated Lc-Maf bound to the wild-type 27F/G probe, producing a
shifted complex indicated by the arrow (Fig. 7D). Formation of this complex was
impaired by addition of the c-Maf antibody. The same 2-basepair mutation that
eliminated the ability of the 27F/Gm enhancer to respond to Lc-Maf in the reporter assays
also impaired Lc-Maf binding to the 27F/Gm enhancer element in EMSA, suggesting that
Lc-Maf binds in this region despite the absence of a previously-identified consensus
sequence (Fig. 7D).

Col11a2 and Lc-Maf exhibit expression patterns that are inversely related.
To observe the expression patterns of Lc-Maf, Col11a2 and Col27a1 during
endochondral ossification of the developing limbs, we performed in situ hybridizations
on the forelimbs of mouse embryos at half day intervals between embryonic days 15 and
17 (E15-E17), which represented a time interval directly before and after ossification
began. A probe directed against Col10a1, a marker for prehypertrophic and hypertrophic
chondrocytes, was included as a control. We found Lc-Maf to be weakly expressed. It is
likely that the splice variant coding for Lc-Maf is of relatively low abundance. We did
observe, however, that the most prominent Lc-Maf expression was in the prehypertrophic
and hypertrophic zones, with only low levels of expression in the resting and proliferative
zones (Fig. 8). The Lc-Maf transcript was consistently present at several time points in
the prehypertrophic and hypertrophic zones both before and after mineralization at the
diaphysis had begun. In contrast, Col11a2 mRNA was most strongly expressed in the
resting and proliferating zones as previously reported (Fig. 8). Together with our
transfection data, this inverse pattern of expression supports the hypothesis that Lc-Maf
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Figure 8. Expression patterns of Col11a2, Col27a1, and Lc-Maf during
endochondral ossification in the murine forelimb. In situ hybridization on longitudinal
sections of the radius of mouse embryos at E15, prior to the onset of mineralization, and
E17, after the onset of mineralization. Panels are arranged with the diaphysis at the left.
Expression of Col10a1 was observed in hypertrophic and prehypertrophic chondrocytes
as expected. Lc-Maf RNA was detected most strongly in the hypertrophic and
prehypertrophic zones. Col11a2 mRNA expression was detected in the resting and
proliferative zones but declined through the prehypertrophic, until fully absent in the
hypertrophic zone. Col27a1 mRNA was detected in the resting, proliferating and
prehypertrophic chondrocytes but not in the hypertrophic zone. Scale bar, 200 µm. h,
hypertrophic; ph, prehypertrophic; p, proliferative; r, resting chondrocytes.
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represses transcription of Col11a2 as chondrocytes enter the prehypertrophic stage of
their differentiation during limb development. Immunohistochemistry analyses performed
by others have shown type XXVII collagen protein to be present only in hypertrophic
chondrocytes (Hjorten, 2007). Our immunohistochemistry analyses gave similar results.
In mouse forelimb growth plate sections from the same mice as those sections used for in
situ hybridization, type XXVII collagen protein was detectable in both prehypertrophic
and hypertrophic chondrocytes but not detected above background levels in the resting or
proliferating zones of developing bone, similar to the expression pattern of Lc-Maf (Fig.
9).
To our surprise, in situ hybridization in mouse limb growth plates revealed that
Col27a1 mRNA was present in resting, proliferating and prehypertrophic chondrocytes
but was not detectable in the hypertrophic zone (Fig. 8). To confirm this unexpected
result, we generated a second probe directed against the third exon of Col27a1 rather than
the 3′UTR; again, Col27a1 mRNA was detectable in the resting, proliferating and
prehypertrophic chondrocytes but not in the hypertrophic zone (data not shown). These
results have been further confirmed in human growth plate by R. Hjorten et al. using laser
capture microdissection followed by quantitative RT-PCR: cells from the proliferative
zone had 16 times more COL27A1 transcript than cells in the hypertrophic zone (Hjorten,
2007).The expression patterns of Lc-Maf and Col27a1 in mouse forelimb growth plate,
therefore, overlap only in the prehypertrophic zone.
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Figure 9. Murine type XXVII collagen protein is present in prehypertrophic and
hypertrophic chondrocytes of bones undergoing endochondral ossification. (A)
Longitudinal section of a digit at E16, prior to the onset of mineralization. (B)
Longitudinal section of a radius at E16, showing the mineralized portion of the diaphysis
at left. (C) Longitudinal section of an ulna at E17, showing the mineralized portion of
the diaphysis at left. Immunohistochemistry was performed using a primary antibody
directed against mature type XXVII collagen and a FITC-labeled secondary antibody.
Scale bar, 200 µm. h, hypertrophic; ph, prehypertrophic; p, proliferative; r, resting
chondrocytes.
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DISCUSSION
The cell-type-specificity and timing of gene expression during chondrogenesis is
largely managed by a delicate balance of positive and negative mediators of transcription.
Proper expression of Col11a2, for example, is mediated in part by three cartilage-specific
enhancer elements that Sox9 binds in order activate expression of the gene (Bridgewater
et al., 1998; Bridgewater et al., 2003; Liu et al., 2000; Tsumaki et al., 1998).
Interestingly, evidence suggests that one of the cartilage-specific elements has dual
activities: it not only directs transcription of Col11a2 in cartilage by binding positive
regulators of transcription, but it also inactivates transcription of Col11a2 in neural tissue
by binding negative regulators of transcription (Tanaka et al., 2002; Tsumaki et al.,
1998).
Individual transcription factors can also regulate in both a positive and a negative
manner. Several bZIP family proteins, for example, have been shown to both activate and
repress transcription at different promoters (Dhakshinamoorthy and Jaiswal, 2002; Li et
al., 1999; Tone et al., 1999). c-Maf has been shown to activate the expression of genes
such as L7, p53 and interleukin-4 and to repress expression of genes such as quinone
oxidoreductase1 (NQO1) and glutathione S-transferase Ya subunit (GST Ya)
(Dhakshinamoorthy and Jaiswal, 2002; Hale et al., 2000; Ho et al., 1996; Kurschner and
Morgan, 1995). Here we demonstrate that the newest addition to the Maf family of
transcription factors, Lc-Maf, is also capable of imposing both positive and negative
regulation, as shown here with our work on several cartilage-specific collagen enhancers.
The primary goal of the research presented here was to determine whether Lc-Maf
activated other developmentally important cartilage-specific enhancer elements in
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addition to the Col2a1 48-bp enhancer that was previously demonstrated (Huang et al.,
2002). Unexpectedly, we found that Lc-Maf may play a more complicated role in the
transcriptional regulation of cartilage-specific collagen enhancers beyond simple
activation. Despite having sequences similar to the Lc-Maf binding sequence reported for
the Col2a1 48-bp enhancer, the Col11a2 B/C and D/E enhancer elements were inhibited
by Lc-Maf. The Col11a2 F/G and COL27A1 27D/E enhancer elements also contained
sequences similar to the reported Lc-Maf binding sequence and yet Lc-Maf had no
regulatory effect on them. Most surprising was the COL27A1 27F/G enhancer element,
which contains neither the consensus Lc-Maf binding sequence nor any known Maf
recognition sequence, but was strongly activated by Lc-Maf. These unexpected results
led us to examine the effect of Lc-Maf on the Col2a1 4x48 enhancer in our BALB/3T3
fibroblasts and RCS cells. While Lc-Maf has been shown to increase Col2a1 expression
in 10T1/2 cells and MC615 mouse immortalized chondrocytes (Huang et al., 2002), the
results of our transient transfection experiments in BALB/3T3 and RCS cell lines showed
that Lc-Maf either repressed the 4x48 enhancer or had no effect on the enhancer,
respectively (data not shown). These results are consistent with the in vivo results from
the c-maf-null mice that also lack Lc-Maf and had normal levels of Col2a1 expression
(MacLean et al., 2003). Taken together, these analyses demonstrate the variability
between tissue culture lines and the importance of animal models
The ability of Lc-Maf to negatively regulate Col11a2 cartilage-specific enhancer
elements and positively regulate a COL27A1 cartilage-specific enhancer element could
have biological relevance in the context of a developing vertebrate by coordinating the
expression of the cartilage-specific collagen genes during development of the long bones.
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It has been reported that Col11a2 mRNA and protein are primarily expressed by
chondrocytes in the resting and proliferative zones of the cartilaginous bone templates
undergoing endochondral ossification and not by chondrocytes in the hypertrophic zone
(Swoboda et al., 1989; Tanaka et al., 2002). Our data support these findings. Mature type
XXVII collagen, on the other hand, is strongly concentrated in regions preparing to go
through mineralization such as the hypertrophic zones and the diaphisial perichondrium
(Hjorten, 2007) (Fig. 9). These differential expression patterns not only suggest a
functional difference between the two gene products but also the need for a strict
transcriptional control of when and where these collagen genes are expressed. We
hypothesized that Lc-Maf could play a role in activating the expression of Col27a1 in the
hypertrophic chondrocytes while serving the dual role of repressing the expression of
Col11a2 in those cells. Indeed, our in situ hybridization results show Lc-Maf mRNA in
the prehypertrophic and hypertrophic zones of the developing limb where it likely plays a
role in repressing the expression of Col11a2.
We expected to see Col27a1 mRNA restricted to the prehypertrophic and
hypertrophic zones since that is where the mature protein is localized and where Lc-Maf
is present to activate its expression in the developing limb. Unexpectedly, the Col27a1
probe directed against the 3′UTR revealed mRNA throughout the resting, proliferative
and into the prehypertrophic zones but not in the hypertrophic zone. We constructed a
second Col27a1 probe directed against the translated third exon and again observed the
same pattern of expression. Consistent with these results, laser capture microdissection
followed by quantitative RT-PCR on human growth plate cells revealed 16-fold more
COL27A1 transcript in proliferative chondrocytes than in hypertrophic chondrocytes
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(Hjorten, 2007). Previous work demonstrated that several splice variants of the Col27a1
gene exist (all of the major variants contained the third exon, to which our second in situ
hybridization probe anneals). Interestingly, the authors reported that one of the splice
variants “was retained in the nucleus, and therefore would not be translated into protein”
(Pace et al., 2003). It is possible that the Col27a1 transcript we identified in the resting
and proliferative zones is a splice variant of a non-translated variety, either nuclear or
cytoplasmic. The data presented here, together with the prior work of others (Pace et al.,
2003) is consistent with the following model: as cells enter the prehypertrophic stage
and begin expressing the transcription factor Lc-Maf, it binds to the Col27a1 27F/G
enhancer and triggers transcription of a short-lived, translatable Col27a1 mRNA. The
resulting mature type XXVII collagen protein remains present and detectable in cells as
they progress from prehypertrophic to hypertrophic chondrocytes, even though the shortlived transcript is quickly degraded and is therefore not detectable by in situ hybridization
in hypertrophic chondrocytes.
It is likely that a unique binding partner for Lc-Maf is expressed in
prehypertrophic chondrocytes. The expression of this binding partner would allow LcMaf to recognize and activate the Col27a1 27F/G enhancer element, triggering
expression of the translatable transcript. The fact that no previously recognized consensus
binding sequence for Maf transcription factors could be identified within the 27F/G
enhancer implies that this protein has not previously been identified as a Maf binding
partner.
Proper expression of the chondrocyte-specific collagens during endochondral
ossification is necessary for correct skeletal development (Farquharson and Jefferies,
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2000; Huang et al., 2002; Okazaki and Sandell, 2004; Velleman, 2000). In 2003,
MacLean et al. demonstrated that c-maf-null mice, which lack both c-Maf and Lc-Maf,
have abnormal chondrocyte development. These mice demonstrated delayed hypertrophic
chondrocyte differentiation and reduced fetal bone length (MacLean et al., 2003). These
results complement and are consistent with the data presented here, which suggest that
the transcription factor Lc-Maf coordinates Col11a2 and Col27a1 collagen gene
expression during the developmental transition from proliferating to hypertrophic
chondrocytes.
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APPENDIX
M9 medium (1 Liter)
1×
11.33 g Na2HPO4·7H2O
3 g KH2PO4
1 g NH4Cl
0.5 g NaCl
Autoclave
M63 minimal plates
1L 5× 10 g (NH4)2SO4
68 g KH2PO4
2.5 mg FeSO4·7H2O
adjust to pH 7 with KOH
Autoclave
Other: 0.2 mg/mL d-biotin (sterile filtered) (1:5000)
0.2 mg/mL d-biotin (sterile filtered) (1:5000)
20% galactose (autoclaved) (1:100)
20% 2-deoxy-galactose (autoclaved) (1:100)
20% glycerol (autoclaved) (1:100)
10 mg/mL L-leucine (1%, heated, then cooled and sterile filtered)
25 mg/mL Chloramphenicol in EtOH (1:2000)
1 M MgSO4·7H2O (1:1000)
Autoclave 15 g agar in 800 mL H2O in a 2 liter flask; let cool a little. Add 200 mL
autoclaved 5× M63 medium and 1 mL 1 M MgSO4·7H2O. Adjust volume to 1 L with
H2O if necessary. When cooled to 50°C, add 10 mL carbon source (final conc. 0.2%), 5
mL biotin (1 mg), 4.5 mL leucine (45 mg), and 500 mL Chloramphenicol (final conc.
12.5 mg/ml). Pour the plates.
MacConkey indicator plates
Prepare MacConkey agar plus galactose according to manufacturer’s instructions. After
autoclaving and cooling to 50°C, add 500 mL Chloramphenicol (final conc. 12.5 mg/mL)
to one L, and pour the plates.

Maintenance of ES cells and aggregation:
MEF Media:
10% FBS
10 mL FBS (do not refreeze)
1 mL 10mM MEM Non Essential amino acids (store at 4°C)
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1 mL 10mM β-Mercaptoethanol (store at 4°C, good for 1 week)
1 mL 200mM L-Glutamine (store at -20°C)
1 mL 5mg/mL Pen/Strep (store at -20°C)
85 mL DMEM, Gibco, High Glucose
ES Media:
15% FBS
15 mL FBS (do not refreeze)
1 mL 10mM MEM Non Essential amino acids (store at 4°C)
1 mL 10mM β-Mercaptoethanol (store at 4°C, good for 1 week)
1 mL 200mM L-Glutamine (store at -20°C)
1 mL 5mg/mL Pen/Strep (store at -20°C)
100 µL LIF 10E6 (store at 4°C)
80.9 mL DMEM, Gibco, High Glucose
M2 media:
15% FBS
15 mL FBS (do not refreeze)
1 mL 10mM MEM Non Essential amino acids (store at 4°C)
1 mL 10mM β-Mercaptoethanol (store at 4°C, good for 1 week)
1 mL 200mM L-Glutamine (store at -20°C)
1 mL 5mg/mL Pen/Strep (store at -20°C)
90 mL HEPES-buffered DMEM, Gibco, High Glucose
Freezing media:
2X:
2 mL FBS
2 mL DMSO
6 mL MEF Media
Stock Solutions
FBS: thaw, heat inactivate 30 minutes at 55°C, aliquot (store at -20°C until use)
1000X solutions:
200 mg/mL active G418 in PBS, filtered (store at -20°C)
0.1 mM FIAU in PBS, filtered (store at -20°C)
10E7 units LIF (Gibco) resuspended in 10 mL DMEM (store at
4°C)
100X solutions
10 mM MEM Non Essential A.A., aliquot (store at 4C)
10mM β-Mercaptoethanol (3.5 µL into 5 mL PBS, filter, store at
4°C, good for 1 week)
200 mM L-Glutamine, aliquot (store -20°C)
5 mg/mL Pen/Strep, aliquot (store -20°C)
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